For over 22 years pancreatica.org has provided current, credible, and comprehensive information to those in need.
Cancer Patient’s Alliance is a 501(c)(3) non-profit organization. All donations are tax-deductible.

94% of all revenue goes towards our programs, with only 6% towards MANAGEMENT AND GENERAL EXPENSES.

NEUROENDOCRINE TUMORS, ISLET-CELL AND CARCINOID TUMORS

Neuroendocrine tumors of the pancreas (islet cell tumors) are much less common than tumors arising from the exocrine pancreas. Reports often indicate that there are about two to three thousand cases diagnosed in the U.S. each year – although autopsy indicates that there may be a higher incidence of these islet cell tumors than are diagnosed.

The general term used tends to be “neuroendocrine” as these tumors may arise IN or ASSOCIATED WITH the hormone producing areas of the very complicated organ which is the pancreas. This hormone producing area is termed endocrine, and the other main area which tends to produce pancreatic “juice” that makes its way to the intestine to aid in digestion is called the exocrine pancreas. These different areas of the pancreas are somewhat jumbled up together anatomically – so rather than being like neighbors, the endocrine and exocrine areas of the pancreas are more like ethnicities all living together in the city known as the pancreas. The term “islet cell tumor” is another word for neuroendocrine tumor.

About 75% of neuroendocrine tumors are “functioning.” That is they are found to be producing symptoms related to one or more of the hormone peptides that they secrete. About one quarter of islet cell tumors do not produce symptoms related to hormone secretion and thus are termed non-functioning. The predominant hormone peptide being secreted gives the functioning islet cell tumor its name. There are a surprising number of these hormonal peptides that islet cell tumors have been found to secrete; some are not even related to the pancreas. This array includes insulin, gastrin, glucagon, somatostatin, neurotensin, pancreatic polypeptide (“PP”), vasoactive intestinal peptide (“VIP”), growth hormone releasing factor (“GRF”), ACTH and others. Some of these are very rare.

Apart from producing no currently discernible hormone peptide, non-functioning tumors may include those which produce PP (“PPomas”) or neurotensin (“neurotensinomas”), as these hormones usually produce no symptoms. The most common functioning pancreatic endocrine tumors are insulinomas followed by gastrinomas, glucagonomas and VIPomas, respectively. Typically, the symptoms produced by the excess secretion of the predominant hormone in a given functioning endocrine tumor, drives the eventual diagnosis.

With the exception of insulinomas, most of the islet cell tumors have fairly similar characteristics, belying the apparent differences caused by the large range of symptom effects related to the secretion of such different hormones. Histologically (under the microscope) they tend to be quite similar. It is not possible to ascertain malignancy from the histological appearance; malignancy is seen primarily as a function of finding additional metastatic sites. Except for insulinomas, very roughly about 60% of islet cell tumors are malignant. This rate contrasts with about 10% of insulinomas which are eventually found to be malignant. The sites of metastasis of islet cell tumors most commonly are the liver and the lymph nodes in the vicinity of the pancreas.

Insulinomas are islet cell tumors which secrete an excess of (predominantly) insulin. These tumors will typically first present symptoms between the ages of 40 and 50, are more common among women and tend to be small, solitary tumors located in the pancreas itself. The clinical features of this tumor are related to the effects of insulin-and thus primarily demonstrate symptoms related to hypoglycemia which are relieved by food intake. Other general symptoms include episodic sweating, tremor and rapid heart rate, as well as hunger, nausea, weight gain, and sometimes even central nervous system symptoms (including rarely, seizures).

Gastrinomas over-secrete the hormone gastrin. The clinical effect of this circumstance is what has come to be called the Zollinger-Ellison syndrome, a triad of signs and symptoms including atypical peptic ulcer disease, gastric hyperacidity and hyper-secretion, and an associated islet cell pancreatic tumor. About 2% of patients with non-healing peptic ulcers (after receiving an appropriate therapy regimen) are found to have Z-E syndrome with its attendant tumor. Most patients are male (~60%) and the average age at diagnosis is about 60 years.
Patients with glucagonomas tend to present with mild diabetes and a severe dermatitis. These tumors are frequently fairly large by the time of diagnosis, sometimes greater than two inches in diameter. Approximately 70% of these tumors are malignant. About 80% of VIPomas are located in the pancreas itself-the rest elsewhere. Over-secretion of this vasoactive intestinal peptide causes watery diarrhea, and low serum potassium and chloride levels. Only about 200 cases of this kind of tumor have been described in the medical literature; the majority are malignant by the time of diagnosis.

Carcinoid cancer is the most common of the neuroendocrine tumors, with one-and-a-half diagnosed cases per 100,000 of population, although anatomy at autopsy demonstrates about 400 times those that are diagnosed clinically. They tend to be slow growing. The symptoms and signs of carcinoid tumors range widely, and depend on the location and size of the tumor, on the presence of metastases, and secretions. They can appear to the surgeon as firm nodules bulging into the intestinal lumen (can originate from pancreas, lungs, thymus, appendix, and ovaries, etc.), with possible local expansion, and possible metastases to mesenteric lymph nodes, liver, ovaries, peritoneum, testes, prostate, spleen and other anatomic locations. Carcinoid tumors can secrete any number of hormonal, growth and other factors. Symptoms related to the tumor and its factors may be intermittent and vague, but the most common presentation is periodic abdominal pain sometimes accompanied by malignant carcinoid syndrome, characterized by flushing of the face, severe diarrhea, and an asthma episode. The initial evaluation of patients often includes measurement of such factors as serotonin, 5-HT, catecholamines and histamine, and especially urinary 5-HIAA levels. In general, survival rates for patients with carcinoid cancers are related to the size of the primary tumor – and the degree of metastasis.

The natural history of islet cell and carcinoid tumors tends to be favorable as compared with pancreatic adenocarcinoma. For example, the median survival duration from the time of diagnosis for patients with non-functioning metastatic islet cell tumors approaches five years. The diagnosis of islet cell tumors is aided by the different abnormal biochemical profiles that they may present, which often leads to radiographic means to try and locate the tumor. It would be a mistake to generalize too much about attempts to locate these tumors. But generally, dynamic CT scans with radio-contrast dye, octreotide scintigraphy, transabdominal ultrasound, and selective visceral angiography are all methods employed to elicit radiographic information about the cancer, depending on individual circumstance.

Patients with glucagonomas tend to present with mild diabetes and a severe dermatitis. These tumors are frequently fairly large by the time of diagnosis, sometimes greater than two inches in diameter. Approximately 70% of these tumors are malignant. About 80% of VIPomas are located in the pancreas itself-the rest elsewhere. Over-secretion of this vasoactive intestinal peptide causes watery diarrhea, and low serum potassium and chloride levels. Only about 200 cases of this kind of tumor have been described in the medical literature; the majority are malignant by the time of diagnosis.

Carcinoid cancer is the most common of the neuroendocrine tumors, with one-and-a-half diagnosed cases per 100,000 of population, although anatomy at autopsy demonstrates about 400 times those that are diagnosed clinically. They tend to be slow growing. The symptoms and signs of carcinoid tumors range widely, and depend on the location and size of the tumor, on the presence of metastases, and secretions. They can appear to the surgeon as firm nodules bulging into the intestinal lumen (can originate from pancreas, lungs, thymus, appendix, and ovaries, etc.), with possible local expansion, and possible metastases to mesenteric lymph nodes, liver, ovaries, peritoneum, testes, prostate, spleen and other anatomic locations. Carcinoid tumors can secrete any number of hormonal, growth and other factors. Symptoms related to the tumor and its factors may be intermittent and vague, but the most common presentation is periodic abdominal pain sometimes accompanied by malignant carcinoid syndrome, characterized by flushing of the face, severe diarrhea, and an asthma episode. The initial evaluation of patients often includes measurement of such factors as serotonin, 5-HT, catecholamines and histamine, and especially urinary 5-HIAA levels. In general, survival rates for patients with carcinoid cancers are related to the size of the primary tumor – and the degree of metastasis.

The natural history of islet cell and carcinoid tumors tends to be favorable as compared with pancreatic adenocarcinoma. For example, the median survival duration from the time of diagnosis for patients with non-functioning metastatic islet cell tumors approaches five years. The diagnosis of islet cell tumors is aided by the different abnormal biochemical profiles that they may present, which often leads to radiographic means to try and locate the tumor. It would be a mistake to generalize too much about attempts to locate these tumors. But generally, dynamic CT scans with radio-contrast dye, octreotide scintigraphy, transabdominal ultrasound, and selective visceral angiography are all methods employed to elicit radiographic information about the cancer, depending on individual circumstance.

Although they arise from similar cells, these different types of neuroendocrine cancers all behave somewhat differently. The standard treatments tend to be tumor-type specific, but some general observations can be made. Immediate treatment of the symptomatic conditions created by the over-secretion of the hormone(s) may be appropriate. (For example, the use of H2-blockers, omeprazole and even octreotide in gastrinomas). The treatment of choice for localized islet cell tumors is generally curative surgery. The treatment of metastatic islet cell cancer disease, depending on the tumor type, will often include chemotherapy involving such agents as streptozocin, everolimus, sunitinib, temozolomide, capecitabine, 5-FU, doxorubicin, dacarbazine and octreotide. Recently, there have been published in the medical literature promising studies of aggressive surgery benefiting select cases of metastatic neuroendocrine tumors.

Apparently isolated liver metastases have been treated with such creative approaches as hepatic artery embolization. This may reduce the nutrient blood supply to the metastatic liver tumor (which tend to be rather vascular), but this approach remains controversial. It is difficult per the limits of today’s radiographic methods (and even via direct inspection at surgery) to fully appreciate the presence of small tumors in the liver-thus there well may be more metastases that have been undetected. Currently, there are studies employing techniques of radioimmunotherapy to selected patients with metastatic islet cell cancer, wherein radioactive elements have been conjugated together with specific compounds (sometimes hormonal elements) which are chosen for their properties that tend to selectively target islet cell tissue. These are very interesting early studies which hold the virtue of biologic plausibility, but the final results of the efficacy of this approach is not yet fully known.

Some percentage of islet cell tumors may be a part of several well-defined hereditary syndromes in which the tendency exists for the development of tumors in various (typically multiple) endocrine glands in the body, and which are known as the multiple endocrine neoplasia (or “MEN”) syndromes.

Our science board is composed of:

James Abbruzzese, MD Chief, Medical Oncology Duke University

Markus Büchler, MD Chairman, Surgery Heidelberg University, Germany

Ralph Hruban, MD Director, GI / Liver Pathology Johns Hopkins University

Eileen O’Reilly, MD Associate Director for Clinical Research – Memorial Sloan-Kettering Cancer Center

Margaret Tempero, MD Chief, Medical Oncology University of California at San Francisco

Our Philosophy About Pancreatic Cancer

Pancreatic cancer is a serious disease. Taking an aggressive rational stance at the earliest possible time, supported by the best medical team, and treated in the most appropriate manner gives the best chance for survival.

We believe in strong patient-physician bonds, scientifically-based treatment, and that comfort can come from knowing that everything that reasonably can be done – is being done.

That the best approach is meeting cancer of the pancreas head-on and armed with the best available information.

MONTHLY MEMORIAL GIFTS:  YOUR TRIBUTE TO A LOVED ONE

Regular giving can be an opportunity to pay tribute in honour of a loved one. Your monthly gift will go directly to promoting awareness, increasing education, furthering pancreatic cancer research aimed at early diagnosis and, helping patients and families impacted by the effects of pancreatic cancer.

Simply select “Monthly” after choosing the amount you would like to give on the donation form.

ABSTRACTS:

The following are descriptions of titles of abstracts of medical journal articles that may be interesting or useful to those who are interested in further information about this topic. 

PRRT + capecitabine + temozolomide for Met NET
1/23/2024
Link to Abstract

Radiation Risk from NET Surveillance
1/19/2024
Link to Abstract

PRRT for Insulinomas
12/21/2023
Link to Abstract

Dosimetry-guided PRRT treatment for NETs ?
12/21/2023
Link to Abstract

Liver Rx May Benefit Even with Extensive Other Mets
12/13/2023
Link to Abstract

Hepatic thermal ablation + chemoembolization
12/18/2023
Link to Abstract

Cabozantinib for NETs
12/1/2023
Link to Abstract

Chromogranin A Increased by Proton Pump Inhibitors
10/11/2023
Link to Abstract

Treatment of Advanced Pheochromocytomas/Paragangliomas
11/8/2023
Link to Abstract

Phase 2 Results: Temodar + Afinitor for high-grade NETS
10/23/2023
Link to Abstract  

Xeloda + Temodar for NETs
10/1/2023
Link to Abstract  

Microwave Ablation for Hepatic METs in NET
9/26/2023
Link to Abstract

Liver transplant for NETs – Outcomes
9/23/2023
Link to Abstract

Prognostic Indicators with MIBG for Advanced Pheos & Paras
9/19/2023
Link to Abstract

Drug/Bead Transarterial Chemoembolization for Liver METS
9/1/2023
Link to Abstract

Diagnosis and Treatment of Pheos and Paras
8/1/2023
Link to Abstract

NET Guide for Adults per PDQ
6/26/2023
Link to Abstract

Prognosis of Peptide Receptor Radionuclide Therapy
6/6/2023
Link to Abstract 

Liver Surgery Confers Survival Advantage in NET Mets
5/1/2023
Link to Abstract

Seratonin Antogonists for Carcinoid Tumors
4/20/2023
Link to Abstract

Telotristat May Also Inhibit NET growth
4/8/2023
Link to Abstract

Surgery for Hepatic METS
4/1/2023
Link to Abstract 

Complications of Reduction Liver Surgery in NETS
4/4/2023
Link to Abstract 

Controlling Breakthrough Symptoms of Carcinoid Syndrome
3/30/2023
Link to Abstract

Genetic Variability and Precision Medicine in NETs
3/1/2023
Link to Abstract

Treatment Options for Grade III GI NETs
3/1/2023
Link to Abstract

EU Working Group Guidance for GI NETs
3/1/2023
Link to Abstract

PRRI for Pheos & Paras
2/13/2023
Link to Abstract

SSAs for GI Disturbance in Carcinoid Syndrome
2/9/2023
Link to Abstract

Patient Administered Tools for Assessment of NETs
2/3/2023
Link to Abstract

State of Liver Transplants for Advanced NETS
1/17/2023
Select Abstract

Timing of SSAs before PRRT for neuroendocrine Tumors
1/4/2023
Select Abstract

I-131 Biomarker for Pheochromocytoma & Paraganglioma
1/1/2023
Link to Abstract  

Prognostic markers for [131I]MIBG therapy for PPGLs
1/1/2023
Link to Abstract  

Muscle loss and white cell ratio as prognostic indicators in NET
1/1/2023
Link to Abstract 

Phase 2 Clinical Trials: 177LU-PRRT for NETs
12/7/2022
Link to Abstract

Obesity Paradox: Risk AND Protection in NETs
11/21/2022
Link to Abstract 

Radiopharmaceuticals for PPGLs
11/16/2022
Link to Abstract 

Model Schema Predicts Longevity with Liver NET
11/8/2022
Link to Abstract 

Is Afinitor Plus PRRT for NETS Feasible ?
11/4/2022
Link to Abstract 

Hepatic Surgery or Transplant for Hepatic mets
11/1/2022
Link to Abstract 

Targeted radionuclide therapy for PHEO & PGL
10/20/2022
Link to Abstract 

Preliminary: Cytokine Panel for NET Diagnosis ?
10/20/2022
Link to Abstract

Carcinoid Syndrome Improved with Telotristat Ethyl
10/17/2022
Link to Abstract

Stable weight in Carcinoid with Telotristat Ethyl
10/1/2022
Link to Abstract

NETs: metronomic Capecitabine or Temozolomide
10/1/2022
Link to Abstract 

Propensity Scores to Guide Post-surgical Radiotherapy
9/17/2022
Link to Abstract

Phase 2: Zepzelca for NETs ?
9/1/2022
Link to Abstract

PDQ: Treatment for Carcinoid Tumors
8/19/2022
Link to Abstract 

Preclinical: CAR-T Cells for NETs
8/18/2022
Link to Abstract

CAPTEM + Octreotide or Lanreotide in Advanced NETS
8/16/2022
Link to Abstract

Genetic Blood-based Serial Observation in NET Treatment
8/11/2022
Link to Abstract 

Case Study: Salvage PRRT Post-remission
8/1/2022
Link to Abstract 

225Ac-DOTATATE TAT + Xeloda for Advanced NETs
7/21/2022
Link to Abstract 

Radioembolization for Hepatic NET Mets
7/14/2022
Link to Abstract

Treament for Carcinoid
7/1/2022
Link to Abstract 

Significant Response of NET of Unknown Primary to 225Ac-DOTATATE
6/27/2022
Link to Abstract 

Case: Afinitor for poorly differentiated NET from an unknown primary
6/24/2022
Link to Abstract 

MIBG for Pheochromocytomas
6/1/2022
Link to Abstract 

Radiopharmacal mIBG for PPGLs
6/1/2022
Link to Abstract 

Mental Health After NET Surgery
6/1/2022
Link to Abstract

Tailoring 177Lu-DOTATATE Dose in PRRT
6/1/2022
Link to Abstract

Platinum Combination Therapy for Advanced NETs
5/30/2022
Link to Abstract 

Case Report: Complete Response of Liver Met to Chemoembolization
5/25/2022
Link to Abstract

SSAs of No Advantage after PRRT in well-differentiated NETs ?
5/3/2022
Link to Abstract

Liver or Blood Toxicity 12 Months Post-PRRT
5/1/2022
Link to Abstract

High-dose SSAs for Neuroendocrine Tumors?
5/1/2022
Link to Abstract

Severe Platelet Loss with PRRT for Advanced NETs
5/1/2022
Link to Abstract

Patient Perspectives of Treatment with Somatostatin Analogs
4/27/2022
Link to Abstract 

Biomarkers and CTCs in NETs
4/1/2022
Link to Abstract

SSAs Tend to Cause Increase in Glucose A1c
4/1/2022
Link to Abstract

US Guided RFA for Hepatic Mets in NETs
3/13/2022
Link to Abstract 

I-131 mIBG for Tumor Treatment
3/1/2022
Link to Abstract 

Full Review Article of Treatment Options in NETs
2/27/2022
Link to Abstract

Phase II: (131I-mIBG) for Refractory PHEOs and PPGLs
1/1/2022
Link to Abstract  

Hepatic Resection Confers Survival Advantage in NET Mets
1/1/2022
Link to Abstract 

Extent of NET Prognosis from Liver METS Resection
1/4/2022
Link to Abstract

Telotristat Ethyl for Carcinoid Syndrome
9/27/2021
Link to Abstract

MicroRNAs in NETs
8/9/2021
Link to Abstract

Precsion Medicine and the Treatment of NETs
8/1/2021
Link to Abstract

Ki-67 Levels and Prognosis in NETs
7/26/2021
Link to Abstract

Chemoradiotherapy Prior to Surgery in NENs
7/26/2021
Link to Abstract

Phase II Study of a Novel Somatostatin Receptor Antagonist
7/2/2021
Link to Abstract

Phase II: FOLFIRINEC vs Platinum-etoposide for NETs
7/1/2021
Link to Abstract

Afinitor + Radiotherapy Pilot for Hepatic Mets in NET
6/30/2021
Link to Abstract

Focal, High-dose Radiation for NENs
6/2/2021
Link to Abstract

Phase II: CAPTEM for Advanced NETs
6/1/2021
Link to Abstract

Age Associated with Survival in Liver Transplants in NETs
6/1/2021
Link to Abstract

TELEPATH result: Telotristat Ethyl
5/3/2021
Link to Abstract 

Prognosis of Grade 3 NETs
4/1/2021
Link to Abstract

18F-FDG PET Prior to PRRT- a Useful Tool?
4/1/2021
Link to Abstract

TACE vs. TARE in Hepatic METS in NETs
4/1/2021
Link to Abstract

FDG-PET + Afinitor Survival Advantage in Advanced NETs
4/1/2021
Link to Abstract

Hepatic Radioembolization for METs in NETs
3/1/2021
Link to Abstract

Arterial PRRT for Liver Mets in NET
2/1/2021
Link to Abstract

Blood Biomarkers for NETs
1/21/2021
Link to Abstract

Modes of Embolization for Liver METs in NET
1/3/2021
Link to Abstract 

Blood MicroRNA signatures in NETs
12/31/2020
Link to Abstract 

Safety Profiles of NET Treatments
12/27/2020
Link to Abstract

Epigenetics for Future in NETs
12/15/2020
Link to Abstract

PRRT for Hepatic Mets in NET
12/11/2020
Link to Abstract

Personalized Medicine with PPRT in NETs
11/11/2020
Link to Abstract

NET Surgery Increases Survival Even If Liver Not Treated
12/1/2020
Link to Abstract 

Surgical Results for Locally Advanced NETs of Pancreas
11/4/2020
Link to Abstract

Cutting-edge Immunotherapy Approaches for NETs
10/5/2020
Link to Abstract 

Diazoxide for Insulinoma: case study
10/1/2020
Link to Abstract

NCI PDQ: GI Carcinoid Tumor Treatment
10/1/2020
Link to Abstract 

Precision Medicine Review: NETs
10/1/2020
Link to Abstract

Observation + Surveillance for Small NETs ?
9/16/2020
Link to Abstract

3-drug FOLFIRI as 2nd Line for Advanced NETs
9/12/2020
Link to Abstract

Phase II Results for Nintedanib in NETs
8/15/2020
Link to Abstract

Major Liver Surgery Via Robotics
7/13/2020
Link to Abstract

Laser Ablation for Hepatic Mets in NETS ?
6/21/2020
Link to Abstract

Alpha Interferon for Advanced NET: case study
6/19/2020
Link to Abstract

Stereotactic Radiation for NE Tumors
6/1/2020
Link to Abstract 

Psychological Effects of Afinitor
5/31/2020
Link to Abstract

NCI PDQ: Genetics of NETs
5/29/2020
Link to Abstract

Afinitor and Infection Rates
5/13/2020
Link to Abstract

Second Line Therapy in Metastatic NETs
5/7/2020
Link to Abstract

Longer Term Results with Surgery in NETs
5/5/2020
Link to Abstract

Cinical trial: Cis + Etoposide vs Cis + Irinotecan for NETs
5/1/2020
Link to Abstract

Phase II Trial Resuts for Votrient in NETs
4/7/2020
Link to Abstract

Fixed-dose or Dosimetry PRRT for NETs ?
4/15/2020
Link to Abstract

Review: Hepatic Embolism Treatment in NETS
3/13/2020
Link to Abstract 

Afinitor vs Afinitor + Octreotide for NETs
3/1/2020
Link to Abstract

Alpha Particle Therapy for NETs
3/1/2020
Link to Abstract

Liquid Biopsy as Biomarker for NETs
3/1/2020
Link to Abstract 

SSRIs for Depression in NETS ?
2/10/2020
Link to Abstract

RNA-based Biomarker for NET Management
2/1/2020
Link to Abstract

Radioembolization NET Hepatic Mets post PRRT
2/1/2020
Link to Abstract

Laparoscopic Resection of Small Bowel Carcinoid
1/1/2020
Link to Abstract

CTCs for Prognosis in NETs
12/27/2019
Link to Abstract

Microwave Ablation for Hepatic Mets in NET
12/20/2019
Link to Abstract 

Liver Resection for NET Mets
12/1/2019
Link to Abstract 

African-Americans: Higher Incidence of NETs; Worse Outcomes
12/1/2019
Link to Abstract 

Resection for Advanced Grade NETs ?
11/17/2019
Link to Abstract

increased KI-67 and Tumor Grade: possible biomarkers in NETs
10/29/2019
Link to Abstract

Active Observation for Non-funtioning NETs <1 cm in pancreas
10/2/2019
Link to Abstract 

ALPPS Surgery for Difficult Liver METS in NETs
9/19/2019
Link to Abstract 

Phase II Results of Oral 2nd Generation mTOR Inhibitor for NETs
9/17/2019
Link to Abstract 

Everolimus: tumor control in Germline Mutation NETs
8/1/2019
Link to Abstract 

Complementary Meds used by NET Patients
8/1/2019
Link to Abstract 

Lower dose Sutent may not Effect Efficacy in Pancreatic NETs
8/1/2019
Link to Abstract 

Longer Streptozocin and 5-FU intervals in Pan NETS Maintenance
8/1/2019
Link to Abstract 

Minimally Invasive Vs Open Pancreatectomy for Pan NETs
8/1/2019
Link to Abstract 

Precision Medicine in G3 NETs
7/1/2019
Link to Abstract 

Radioembolization for Liver Mets in NETs
7/1/2019
Link to Abstract 

Specific Gene Mutations May Suggest Unique Treatments
6/3/2019
Link to Abstract 

NETS of Pancreas as High as 4% of Population ?
5/22/2019
Link to Abstract 

Genomic patterns of Neuroendocrine tuomors
4/1/2019
Link to Abstract

Afinitor Better than Sutent for NETs ?
4/1/2019
Link to Abstract 

More complications in Whipple for Pancreatic NETs than Adenocarcinoma
4/1/2019
Link to Abstract 

Safety of Sutent
4/1/2019
Link to Abstract

Epigenetics and genetics of NETs 
4/1/2019
Link to Abstract

Xeloda + Temodal for Advanced NETs 
3/7/2019
Link to Abstract

CAM use by Patients with NETs
3/1/2019
Link to Abstract

Meta -analysis: Efficacy of Afinitor in NETs 
1/1/2019
Link to Abstract

Earlier Possible End Points In Phase II for NETs 
1/1/2019
Link to Abstract

The Prognosis of Lack of Symptom Control in NETs
1/1/2019
Link to Abstract

Lanreotide Autogel for NETs
12/17/2018
Link to Abstract

Afinitor in Combination with Somatostatin Analogs in NETS
12/10/2018
Link to Abstract

Effect of lipids on Afinitor in efficacy in Advanced NETs
12/5/2018
Link to Abstract

Resection of Primary NET Improves Longevity Regardless of Hepatic Rx
12/1/2018
Link to Abstract

New Classification System for Neuroendocrine tumors?
12/1/2018
Link to Abstract

Sutent for NETS in Japan
11/9/2018
Link to Abstract

Genetic subtypes Associated with NET Mets
10/17/2018
Link to Abstract

Biomarker for Streptozocin Efficacy in Neuroendocrine Tumors ?
10/11/2018
Link to Abstract

Combined Xeloda and Temodar for Advanced NETs
10/1/2018
Link to Abstract

Prognosis per MicroRNA patterns in PanNENs
10/1/2018
Link to Abstract

Avastin + Chemo for Poorly-Differentiated Metastatic NETs
10/1/2018
Link to Abstract

Good Results with SSA + PRRT for NETs
10/1/2018
Link to Abstract

Adjusted Hazard Ratio: Sutent vs Afinitor in Advanced pancreatic NETs
10/1/2018
Link to Abstract

Negative Surgical Margins May not Improve Survival in Pancreatic NETs
9/29/2018
Link to Abstract

Natural History and Prognosis of Pancreatic NETs
9/13/2018
Link to Abstract

Ethanol-based Ablation of Small Pancreatic NETs
9/1/2018
Link to Abstract 

Radioembolization + Xeloda/Temodar in NETs with Hepatic Mets
9/1/2018
Link to Abstract

Long-term F/U after PRRT
8/16/2018
Link to Abstract

Sutent RX Changed non-secreting NET to Insulinoma
8/8/2018
Link to Abstract

Metformin + SSA or Afinitor May Give Advantage in Pancreatic NETs
8/1/2018
Link to Abstract

Sutent for Well Differentiated Pancreatic NETs
7/10/2018
Link to Abstract

Sutent for G3 Pancreatic NETs
6/1/2018
Link to Abstract

Neoadjuvant Chemo Regimen for Hepatic Mets in Pancreatic NETs
6/1/2018
Link to Abstract

PRRT for NETs
6/1/2018
Link to Abstract

Signifor for NETs
6/1/2018
Link to Abstract

Afinitor + Octreotide LAR for Nonfunctioning NETs
5/23/2018
Link to Abstract

Improved Outcome by adding PARP Inhibitor to PRRT
5/15/2018
Link to Abstract

Dacarbazine-based Chemo for NETs 
5/1/2018
Link to Abstract 

Octreotide for NETs – Review
4/1/2018
Link to Abstract 

Biomarkers for Sutent in NETs
3/8/2018
Link to Abstract

Radioembolization for Hepatic Met in NETs

3/1/2018
Link to Abstract

Sutent in Pre-treated Pancreatic NET Patients
3/1/2018
Link to Abstract

MGMT as a Biomarker for Xeloda-Temodar Combination in NETs
10/24/2017
Link to Abstract 

Tumor Response as an Indicator for Continued Benefit with Sutent
11/21/2017
Link to Abstract

Dosage for Long-term Sutent in Japanese Cohort with Pancreatic NETS
11/21/2017
Link to Abstract

Lymph Node Criteria Produce Superior Staging Schema than Current Best Practices in Pancreatic NETs
10/20/2017
Link to Abstract

Combining Grading and Staging for Improved Prognosis in Abdominal NETs
10/9/2017
Link to Abstract

Afinitor for Nonfunctioning Pancreatic NETs
10/1/2017
Link to Abstract

Good Response with Microsphere Radioembolization in NET Liver Mets
9/6/2017
Link to Abstract

Surgery Not Observation for Small Non-functioning NETs
9/1/2017
Link to Abstract

Tumor Radiotherapy for Unresectable Pancreatic NETs
9/1/2017
Link to Abstract

Yttrium-90 Microspheres for Hepatic Metastases in NETs
9/1/2017
Link to Abstract

Tegafur/gimeracil/oteracil Plus Temozolomide effective in Advanced NETs
8/17/2017
Link to Abstract

Increased METS Grade in NETs Signals Poorer Outcomes
8/1/2017
Link to Abstract

Alpha Interferon for Management of Advanced Pheochromocytoma and Paraganglioma Tumors
7/26/2017
Link to Abstract

Early: Chloroquine May Augment Sutent in NET Treatment
7/20/2017
Link to Abstract

Afinitor Dose History may Predict Survival Advantage
7/1/2017
Link to Abstract

Laparoscopy Compares Well with Surgery for Non-functioning NE Tumors
6/29/2017
Link to Abstract

Afinitor Also Controls Glucogon and Gastrin in Pancreatic NE Tumors
6/22/2017
Link to Abstract

Etoposide Plus Platinum Regimen for NE Tumors
6/22/2107
Link to Abstract

Tumor Surgery in Advanced NETs May Enhance Survival
5/25/2017
Link to Abstract

Octreotide with Interferon Alpha vs. with Avastin
5/20/2017
Link to Abstract

Chemical Ablation for Pancreatic NET
4/6/2017
Link to Abstract

Afinitor for G3 NE Tumors
3/1/2017
Link to Abstract

Histologic Differentiation Offers Guidance for Treatment Options in NETs
3/1/2017
Link to Abstract

Xeloda plus Temodar for early NETs
3/1/2017
Link to Abstract

Phase III Verification of Sutent Efficacy for Pancreatic NETs
2/1/2017
Link to Abstract

Transarterial Chemoembolization with Streptozotocin for Hepatic Mets in NETs
2/1/2017
Link to Abstract

Primary Tumor Resection with Hepatic Metastasis
2/1/2017
Link to Abstract

Predictive Algorithm for Recurrence in Grade 1/2 Non-functioning NETs
1/3/2017
Link to Abstract

5-Fluorouracil, Adriamycin and Streptozocin as Neoadjuvant Rx in Local Pancreatic NETs
1/1/2017
Link to Abstract

FOLFOX for G1/2 Advanced Neuroendocrine Tumors
1/1/2017
Link to Abstract

Surgery Then PRRT for G1/2 Pancreatic NETS with Hepatic Mets
12/1/2016
Link to Abstract

Afinitor in Japan for metastatic NETs

December 7, 2016
Link to Abstract

Sutent: Minimal Side-effects with Increased Progression Free Survival
December 6, 2016
Link to Abstract 

Afinitor Effective in Taiwan Neuroendocrine Cohort
December 1, 2016
Link to Abstract

Role of Surgery for nonfunctioning NETs
December 1, 2016
Link to Abstract

FOLFOX vs. CAPOX each plus Avastin for Metastatic NETs
November 1, 2016
Link to Abstract

IV Streptozocin for hepatic NET mets
September 23, 2016
Link to Abstract

Proposed new stages criteria for pancreatic NETs
September 19, 2016
Link to Abstract

Dacarbazine for progressive advanced NETs
August 18, 2016
Link to Abstract

Gedatolisib – dual target mTOR kinase inhibitor for NET treatment
August 12, 2016
Link to Abstract

Upcoming study: EUS Ethanol ablation for small NETs
August 1, 2016
Link to Abstract

O(6)-methylguanine-DNA methyltransferase – predictor of Temodal response in NETs?
August 1, 2016
Link to Abstract

Radiotherapy for hepatic NET mets
July 1, 2016
Link to Abstract

Octreotide depot plus Avastin and Perjeta for metastatic NETs
May 27, 2016
Link to Abstract

Pancreastatin as an outcome predictor for NETs
April 1, 2016
Link to Abstract

Active surveillance vs. Surgery in Symptomless Small NETs
April 1, 2016
Link to Abstract

Somatuline Depot For NETs
March 1, 2016
Link to Abstract

Is 1.7 the new 2-cm prognostic inflection point in non-functioning NETS?
March 1, 2016
Link to Abstract

Combination Sugical Procedures Appear Beneficial in Select NETs
February 29, 2016
Link to Abstract

Xeloda Plus Temodal in Advanced NETs
February 9, 2016
Link to Abstract

Ethanol Ablation of NETs
February 1, 2016
Link to Abstract

Hepatic Surgery vs. Medical Treatment for Advanced NETS
January 1, 2016
Link to Abstract

PRRT for advanced NETs
January 1, 2016
Link to Abstract

Induction Rx for metastatic NETs ?
January 1, 2016
Link to Abstract

Hepatic Surgery vs. Medical Treatment for Advanced NETS
January 1, 2016
Link to Abstract

PRRT for NETs
February 1, 2016
Link to Abstract

Surgery Improves Results Even in Metastatic Pancreatic NETs
January 1, 2016
Link to Abstract

Postive Case Study of 70 year old with insulinoma treated with PRRT
January 1, 2015
Link to Abstract

Efficacy of Ki-67 Differental Capability Between Higher and Low-grade Aggressiveness of Pancreatic Neuroendocrine Tumors
December 29, 2015
Link to Abstract

Nonfunctioning Pancreatic NETS: to Operate or Not
December 21, 2015
Link to Abstract

Meta Analysis of the Ki-67 marker for Prognosis in NETs
December 17, 2015
Link to Abstract

Everything Old Becomes new Again: CRP for Prognosis in Pancreatic Neuroendocrine Tumors
December 17, 2015
Link to Abstract

Etoposide plus Carboplatin in NETs
December 5, 2015
Link to Abstract

Platinum-based Combination Chemo for 1st Line in Pancreatica Neuroendocrine Tumors?
December 3, 2015
Link to Abstract

Radio-therapy for Liver Mets in Neuroendocrine Tumors
December 3, 2015
Link to Abstract

Streptozocin in Combination Chemo Regimens for Metastatic Neuroendocrine Tumors
December 2, 2015
Link to Abstract

Afinitor for regulation of Symptoms in NETs
December 1, 2015
Link to Abstract

Early I-131-MIBG Result is a Predictor of Future Response for Advanced pancreatic NETs
December 1, 2015
Link to Abstract

Portal Vein Surgery in Pancreatic NETs
November 1, 2015
Link to Abstract

Induction Therapy with (177)Lu-octreotate for Non-functioning NETs Can Provide Some Patients a Surgical Option
November 1, 2015
Link to Abstract

The Curious Encouraging Pre-clinical Results of Valproate on NET Cells
October 28, 2015
Link to Abstract

Can the Grade of a Metastasis Vary From That of the Primary in Pancreatic NETs?
August 25, 2015
Link to Abstract

Fluorouracil Plus Streptozocin Combination Chemotherapy for Pancreatic NETs
August 7, 2015
Link to Abstract

A Clinical Trial of the PRRT (177)Lu-octreotate Plus Afinitor for Advanced NETs
August 1, 2015
Link to Abstract

Hepatic Transplant for Advanced NETs
August 1, 2015
Link to Abstract

Somatostatin Analogues Plus mTOR Inhibitors (Afinitor and Sutent) for NETs
July 4, 2015
Link to Abstract

Successful Microwave Surgical Ablation via Percutaneous Route for a Patient with Conditions Prohibiting Full Surgery
July 1, 2015
Link to Abstract

Clinical Trial of a VEGF Inhibitor Plus Octreotide in Metastatic and Locally-advanced NETs
June 1, 2015
Link to Abstract

Combination of a Recombinant Human Monoclonal Immunoglobulin G1 Antibody Plus Afinitor and Octreotide LAR for Metastatic NETs
June 1, 2015
Link to Abstract

Could the FOLFOX Combination Chemotherapy Regimen be Considered as 2nd Line for Progressing Neuroendocrine Tumors ?
June 1, 2015
Link to Abstract

Combination Therapy with Torisel Plus Avastin for Pancreatic NETs
May 10, 2015
Link to Abstract

Markers of Sutent Efficacy in Metastatic NETs
March 31, 2015
Link to Abstract

Extended Afinitor Therapy in Pancreatic NETs
March 7, 2015
Link to Abstract

Clinical Trial Implications: Effect of Earlier Somatostatin Analogue Usage on Afinitor in Metastatic NETs
March 3, 2015
Link to Abstract

Considerations of a Clinical Trial: Results of Earlier Chemotherapy on the effect of Afinitor in Metastatic NETs
March 1, 2015
Link to Abstract

Sutent Regulation of Untoward Effects of a VIPoma-related Verner-Morrison syndrome: a two-patient case study
January 1, 2015
Link to Abstract

Addition of I-131-MIBG to (90)Y DOTA Phe1-Tyr3-octreotide as PRRT Therapy for Metastatic NETs
December 14, 2014
Link to Abstract

Xeloda and Avastin for Metastatic NETs: a Clinical Trial
December 1, 2014
Link to Abstract

Clinical Trial: Avastin Plus Fluorouracil and Streptozocin for Advanced Pancreatic NETs
December 1, 2014
Link to Abstract

Is there a Careful Place for the Use of Alpha Interferon in NETs ?
November 1, 2014
Link to Abstract

Temodar Plus Xeloda for Advanced NETs
November 1, 2014
Link to Abstract

Metronomic Xeloda for Pancreatic NETs
October 1, 2014
Link to Abstract

A Review of the 2014 Annual ASCO Convention: Metformin and Other Chemotherapy for Pancreatic Cancer and NETs
July 28, 2014
Link to Abstract

Gleevec as Successful in Treating a Patient with a Neuroendocrine Tumor Containing the Kit Mutation
June 1, 2014
Link to Abstract

Ki-67 as an Aid in the Staging of NETs
June 1, 2014
Link to Abstract

Clinical Trial: PRRT Via 177Lu-DOTATATE for NETs
May 1, 2014
Link to Abstract

The Combination Therapy of Streptozocin Plus Xeloda With and Without Cisplatin for Metastatic Pancreatic NETs
March 1, 2014
Link to Abstract

Metastatic pancreatic neuroendocrine tumors (pNET): placing current findings into perspective.
Phan AT. February 13, 2014
Link to Abstract

Incidental Neuroendocrine Tumors of the Pancreas: MDCT Findings and Features of Malignancy.
Gallotti A, Johnston RP, Bonaffini PA, Ingkakul T, Deshpande V, Castillo CF, Sahani DV. February 1, 2014
Link to Abstract

Single photon emission computed tomography/computed tomography in the evaluation of neuroendocrine tumours: a review of the literature.
Lu SJ, Gnanasegaran G, Buscombe J, Navalkissoor S. February 1, 2014
Link to Abstract

Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database.
Ter-Minassian M, Chan JA, Hooshmand SM, Brais LK, Daskalova A, Heafield R, Buchanan L, Qian ZR, Fuchs CS, Lin X, Christiani DC, Kulke MH. January 14, 2014
Link to Abstract

Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors.
Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME. January 7, 2014
Link to Abstract

PRRT as neoadjuvant treatment in NET.
Sowa-Staszczak A, Hubalewska-Dydejczyk A, Tomaszuk M. January 1, 2014
Link to Abstract

Synchronous resection of primary and liver metastases for neuroendocrine tumors.
Gaujoux S, Gonen M, Tang L, Klimstra D, Brennan MF, D’Angelica M, Dematteo R, Allen PJ, Jarnagin W, Fong Y.
Link to Abstract

Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management.
Lee LC, Grant CS, Salomao DR, Fletcher JG, Takahashi N, Fidler JL, Levy MJ, Huebner M. December 1, 2012
Link to Abstract

A Single Fasting Plasma 5-HIAA Value Correlates With 24-Hour Urinary 5-HIAA Values and Other Biomarkers in Midgut Neuroendocrine Tumors (NETs).
Tellez MR, Mamikunian G, O’Dorisio TM, Vinik AI, Woltering EA. November 15, 2012
Link to Abstract

FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3.
Hentic O, Hammel P, Couvelard A, Rebours V, Zappa M, Palazzo M, Maire F, Goujon G, Gillet A, Lévy P, Ruszniewski P. November 6. 2012
Link to Abstract

Surgical strategies for non-functioning pancreatic neuroendocrine tumours.
Kim MJ, Choi DW, Choi SH, Heo JS, Park HJ, Choi KK, Jang KT, Sung JY. November 1, 2012
Link to Abstract

Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
Claringbold PG, Price RA, Turner JH. November 1, 2012
Link to Abstract

Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study.
Faggiano A, Ferolla P, Grimaldi F, Campana D, Manzoni M, Davì MV, Bianchi A, Valcavi R, Papini E, Giuffrida D, Ferone D, Fanciulli G, Arnaldi G, Franchi GM, Francia G, Fasola G, Crinò L, Pontecorvi A, Tomassetti P, Colao A. October 1, 2012
Link to Abstract

Delay in the diagnosis of multiple endocrine neoplasia type 1: typical symptoms are frequently overlooked.
Yamazaki M, Suzuki S, Kosugi S, Okamoto T, Uchino S, Miya A, Imai T, Kaji H, Komoto I, Miura D, Yamada M, Uruno T, Horiuchi K, Sato A, Miyauchi A, Imamura M, Sakurai A; MEN Consortium of Japan. September 30, 2012
Link to Abstract

Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors.
Chan JA, Ryan DP, Zhu AX, Abrams TA, Wolpin BM, Malinowski P, Regan EM, Fuchs CS, Kulke MH. September 14, 2012
Link to Abstract

Streptozocin-based chemotherapy is not history in neuroendocrine tumours.
Weatherstone K, Meyer T. September 1, 2012
Link to Abstract

Neoadjuvant chemotherapy with capecitabine and temozolomide for unresectable pancreatic neuroendocrine tumor.
Devata S, Kim EJ. September 1, 2012
Link to Abstract

Incidental detection of pancreatic neuroendocrine tumors: an analysis of incidence and outcomes.
Cheema A, Weber J, Strosberg JR. September 1, 2012
Link to Abstract

Metastatic nonfunctioning pancreatic neuroendocrine carcinoma to liver: surgical treatment and outcomes.
Cusati D, Zhang L, Harmsen WS, Hu A, Farnell MB, Nagorney DM, Donohue JH, Que FG, Reid-Lombardo KM, Kendrick ML. July 1, 2012
Link to Abstract

Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis.
Poultsides GA, Huang LC, Chen Y, Visser BC, Pai RK, Jeffrey RB, Park WG, Chen AM, Kunz PL, Fisher GA, Norton JA. July 1, 2012
Link to Abstract

Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy.
Arvold ND, Willett CG, Fernandez-del Castillo C, Ryan DP, Ferrone CR, Clark JW, Blaszkowsky LS, Deshpande V, Niemierko A, Allen JN, Kwak EL, Wadlow RC, Zhu AX, Warshaw AL, Hong TS. July 1, 2012
Link to Abstract

Synchronous Resection of Primary and Liver Metastases for Neuroendocrine Tumors.
Gaujoux S, Gonen M, Tang L, Klimstra D, Brennan MF, D’Angelica M, Dematteo R, Allen PJ, Jarnagin W, Fong Y. July 3, 2012
Link to Abstract

Resected pancreatic neuroendocrine tumors: patterns of failure and disease-related outcomes with or without radiotherapy.
Zagar TM, White RR, Willett CG, Tyler DS, Papavassiliou P, Papalezova KT, Guy CD, Broadwater G, Clough RW, Czito BG. July 15, 2012
Link to Abstract

Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas.
Nakano K, Takahashi S, Yuasa T, Nishimura N, Mishima Y, Sakajiri S, Yokoyama M, Tsuyama N, Ishikawa Y, Hatake K. August 1, 2012
Link to Abstract

Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.
Chan JA, Stuart K, Earle CC, Clark JW, Bhargava P, Miksad R, Blaszkowsky L, Enzinger PC, Meyerhardt JA, Zheng H, Fuchs CS, Kulke MH. August 20, 2012
Link to Abstract

Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas.
Olsen IH, Sørensen JB, Federspiel B, Kjaer A, Hansen CP, Knigge U, Langer SW. August 22, 2012
Link to Abstract

FOLFIRI regimen, an effective second-line chemotherapy after failure of etoposide-platinum combination for patients with neuroendocrine carcinomas grade 3.
Hentic O, Hammel P, Couvelard A, Rebours V, Zappa M, Palazzo M, Maire F, Goujon G, Gillet A, Levy P, Ruszniewski P. August 31, 2012
Link to Abstract

Venous tumor thrombus in nonfunctional pancreatic neuroendocrine tumors.
Balachandran A, Tamm EP, Bhosale PR, Katz MH, Fleming JB, Yao JC, Charnsangavej C. September 1, 2012
Link to Abstract

Lymph nodes and survival in pancreatic neuroendocrine tumors.
Krampitz GW, Norton JA, Poultsides GA, Visser BC, Sun L, Jensen RT. September 1, 2012
Link to Abstract

Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.
Kvols LK, Oberg KE, O’Dorisio TM, Mohideen P, de Herder WW, Arnold R, Hu K, Zhang Y, Hughes G, Anthony L, Wiedenmann B. September 14, 2012
Link to Abstract

Everolimus for Advanced Pancreatic Neuroendocrine Tumours: A Subgroup Analysis Evaluating Japanese Patients in the RADIANT-3 Trial.
Ito T, Okusaka T, Ikeda M, Igarashi H, Morizane C, Nakachi K, Tajima T, Kasuga A, Fujita Y, Furuse J. October 1,2012
Link to Abstract

Laparoscopic surgical exploration is an effective strategy for locating occult primary neuroendocrine tumors.
Massimino KP, Han E, Pommier SJ, Pommier RF.
Am J Surg. 2012 May;203(5):628-31. PMID: 22459446
Link to Abstract

Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms.
Hamilton NA, Liu TC, Cavatiao A, Mawad K, Chen L, Strasberg SS, Linehan DC, Cao D, Hawkins WG.
Surgery. 2012 Apr 11. [Epub]  PMID: 22503317
Link to Abstract

Unusual complication of a pancreatic neuroendocrine tumor presenting with malignant hypercalcemia.
Kanakis G, Kaltsas G, Granberg D, Grimelius L, Papaioannou D, Tsolakis AV, Oberg K.
J Clin Endocrinol Metab. 2012 Apr;97(4):E627-31.  PMID: 22319031
Link to Abstract

Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen?
Mayerhoefer ME, Schuetz M, Magnaldi S, Weber M, Trattnig S, Karanikas G.
Eur Radiol. 2012 Apr;22(4):938-46.  PMID: 22080251
Link to Abstract

Pancreatic Neuroendocrine Tumors With Involved Surgical Margins: Prognostic Factors and the Role of Adjuvant Radiotherapy.
Arvold ND, Willett CG, Fernandez-Del Castillo C, Ryan DP, Ferrone CR, Clark JW, Blaszkowsky LS, Deshpande V, Niemierko A, Allen JN, Kwak EL, Wadlow RC, Zhu AX, Warshaw AL, Hong TS.
Int J Radiat Oncol Biol Phys. 2012 Mar 11. [Epub]  PMID: 22414286
Link to Abstract

Pancreatic Neuroendocrine Tumors: Radiographic Calcifications Correlate with Grade and Metastasis.
Poultsides GA, Huang LC, Chen Y, Visser BC, Pai RK, Brooke Jeffrey R, Park WG, Chen AM, Kunz PL, Fisher GA, Norton JA.
Ann Surg Oncol. 2012 Mar 7. [Epub]  PMID: 22396008
Link to Abstract

Surgical management of insulinomas: short- and long-term outcomes after enucleations and pancreatic resections.
Crippa S, Zerbi A, Boninsegna L, Capitanio V, Partelli S, Balzano G, Pederzoli P, Di Carlo V, Falconi M.
Arch Surg. 2012 Mar;147(3):261-6.  PMID: 22430908
Link to Abstract

EUS-FNA for pancreatic neuroendocrine tumors: a tertiary cancer center experience.
Atiq M, Bhutani MS, Bektas M, Lee JE, Gong Y, Tamm EP, Shah CP, Ross WA, Yao J, Raju GS, Wang X, Lee JH.
Dig Dis Sci. 2012 Mar;57(3):791-800. PMID: 21964743
Link to Abstract

Outcome after laparoscopic enucleation for non-functional neuroendocrine pancreatic tumours.
Fernández-Cruz L, Molina V, Vallejos R, Jiménez Chavarria E, López-Boado MA, Ferrer J.
HPB (Oxford). 2012 Mar;14(3):171-6.  PMID: 22321035
Link to Abstract

Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma.
Lindholm DP, Eriksson B, Granberg D.
Med Oncol. 2012 Mar;29(1):301-3.  PMID: 2119166
Link to Abstract

Outcome after laparoscopic enucleation for non-functional neuroendocrine pancreatic tumours.
Fern�¡ndez-Cruz L, Molina V, Vallejos R, Jim�©nez Chavarria E, L�³pez-Boado MA, Ferrer J.
HPB (Oxford). 2012 Mar;14(3):171-6. PMID: 22321035
Link to Abstract

Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production.
Tsutsumi K, Ohtsuka T, Mori Y, Fujino M, Yasui T, Aishima S, Takahata S, Nakamura M, Ito T, Tanaka M.
J Gastroenterol. 2012 Feb 17. [Epub ahead of print]  PMID: 22350698
Link to Abstract

Incidental Detection of Pancreatic Neuroendocrine Tumors: An Analysis of Incidence and Outcomes.
Cheema A, Weber J, Strosberg JR.
Ann Surg Oncol. 2012 Feb 14. [Epub ahead of print]  PMID: 22350605
Link to Abstract

Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.
Yachida S, Vakiani E, White CM, Zhong Y, Saunders T, Morgan R, de Wilde RF, Maitra A, Hicks J, Demarzo AM, Shi C, Sharma R, Laheru D, Edil BH, Wolfgang CL, Schulick RD, Hruban RH, Tang LH, Klimstra DS, Iacobuzio-Donahue CA.
Am J Surg Pathol. 2012 Feb;36(2):173-84.  PMID: 22251937
Link to Abstract

Safety and efficacy of everolimus in adult patients with neuroendocrine tumors.
Oberstein PE, Saif MW.
Clin Med Insights Oncol. 2012;6:41-51. Epub 2012 Jan 4.  PMID: 22253554
Link to Abstract

Improved diagnostic accuracy for neuroendocrine neoplasms using two chromogranin A assays.
Ramachandran R, Bech P, Murphy K, Dhillo W, Meeran K, Chapman R, Caplin M, Ghatei M, Bloom S, Martin N.
Clin Endocrinol (Oxf). 2011 Dec 16. [Epub ahead of print]  PMID:  22175276
Link to Abstract

Laparoscopic versus open treatment for benign pancreatic insulinomas: an analysis of 89 cases.
Hu M, Zhao G, Luo Y, Liu R.
Surg Endosc. 2011 Dec;25(12):3831-7. PMID: 21656066
Link to Abstract

Non-functioning pancreatic neuroendocrine tumors–a case report and review of literature.
Rampurwala MM, Kumar A, Kannan S, Kowalczyk P, Khera S.
J Gastrointest Cancer. 2011 Dec;42(4):257-62.  PMID: 20967573
Link to Abstract

The outcome of resected cystic pancreatic endocrine neoplasms: A case-matched analysis.
Gaujoux S, Tang L, Klimstra D, Gonen M, Brennan MF, D’Angelica M, Dematteo R, Fong Y, Jarnagin W, Allen PJ.
Surgery. 2011 Nov 15. [Epub ahead of print]  PMID: 22088817
Link to Abstract
http://www.ncbi.nlm.nih.gov/pubmed/22088817

Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian Epidemiological study: THE NET MANAGEMENT STUDY.
Faggiano A, Ferolla P, Grimaldi F, Campana D, Manzoni M, Davì MV, Bianchi A, Valcavi R, Papini E, Giuffrida D, Ferone D, Fanciulli G, Arnaldi G, Franchi GM, Francia G, Fasola G, Crino L, Pontecorvi A,
Tomassetti P, Colao A.
J Endocrinol Invest. 2011 Nov 9. [Epub ahead of print]  PMID:     22080849
Link to Abstract

A long-term survival case of recurrent pancreatic vipoma with liver metastases treated by a combination of surgical resection and loco-regional therapies.
Matsukawa H, Fujiwara Y, Shiozaki S, Takakura N, Aoki H, Ohno S, Ojima Y, Harano M, Kanazawa T, Choda Y, Ninomiya M.
Gan To Kagaku Ryoho. 2011 Nov;38(12):2158-60.   PMID: 22202315
Link to Abstract

Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma.
Brixi-Benmansour H, Jouve JL, Mitry E, Bonnetain F, Landi B, Hentic O, Bedenne L, Cadiot G.
Dig Liver Dis. 2011 Nov;43(11):912-6.  PMID: 21831734
Link to Abstract

Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes.
Roland CL, Bian A, Mansour JC, Yopp AC, Balch GC, Sharma R, Xie XJ, Schwarz RE.
J Surg Oncol. 2011 Oct 17. [Epub] PMID:  22006521
Link to Abstract

Chromogranin A and Neuron-Specific Enolase as Prognostic Markers in Patients with Advanced pNET Treated with Everolimus.
Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, Cherfi A, Oberg KE.
J Clin Endocrinol Metab. 2011 Oct 12. [Epub]  PMID: 21994954
Link to Abstract

The clinical implications and biologic relevance of neurofilament expression in gastroenteropancreatic neuroendocrine neoplasms.
Schimmack S, Lawrence B, Svejda B, Alaimo D, Schmitz-Winnenthal H, Fischer L, Büchler MW, Kidd M, Modlin I.
Cancer. 2011 Oct 11. [Epub] PMID: 21990041
Link to Abstract

Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer.
Epstein AS, Soff GA, Capanu M, Crosbie C, Shah MA, Kelsen DP, Denton B, Gardos S, O’Reilly EM.
Cancer. 2011 Oct 11. [Epub]  PMID: 21989534
Link to Abstract

EUS-FNA for Pancreatic Neuroendocrine Tumors: A Tertiary Cancer Center Experience.
Atiq M, Bhutani MS, Bektas M, Lee JE, Gong Y, Tamm EP, Shah CP, Ross WA, Yao J, Raju GS, Wang X, Lee JH.
Dig Dis Sci. 2011 Oct 1. [Epub]  PMID:  21964743
Link to Abstract

Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period.
Anthony L, Vinik AI.
Pancreas. 2011 Oct;40(7):987-94.  PMID: 21697761
Link to Abstract

New therapeutic options for metastatic malignant insulinomas.
de Herder WW, van Schaik E, Kwekkeboom D, Feelders RA.
Clin Endocrinol (Oxf). 2011 Sep;75(3):277-84.
PMID: 21649688
Link to Abstract

A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.
Kulke MH, Chan JA, Meyerhardt JA, Zhu AX, Abrams TA, Blaszkowsky LS, Regan E, Sidor C, Fuchs CS.
Cancer Chemother Pharmacol. 2011 Aug;68(2):293-300.  PMID: 20960192
Link to Abstract

Prognostic validity of a novel american joint committee on cancer staging classification for pancreatic neuroendocrine tumors.
Strosberg JR, Cheema A, Weber J, Han G, Coppola D, Kvols LK.
J Clin Oncol. 2011 Aug 1;29(22):3044-9.   PMID: 21709192
Link to Abstract

Novel Agents in the Treatment of Unresectable Neuroendocrine Tumors. Highlights from the “2011 ASCO Annual Meeting”. Chicago, IL, USA; June 3-7, 2011.
Oberstein PE, Saif MW.
JOP. 2011 Jul 8;12(4):358-61.  PMID: 21737896
Link to Abstract

Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel).
Khan MS, El-Khouly F, Davies P, Toumpanakis C, Caplin ME.
Aliment Pharmacol Ther. 2011 Jul;34(2):235-42.  PMID: 21585408
Link to Abstract

TNM stage and grade in predicting the prognosis of operated, non-functioning neuroendocrine carcinoma of the pancreas–a single-institution experience.
Sellner F, Thalhammer S, Stättner S, Karner J, Klimpfinger M.
J Surg Oncol. 2011 Jul 1;104(1):17-21.  PMID: 21360536
Link to Abstract

Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor.
Bettini R, Partelli S, Boninsegna L, Capelli P, Crippa S, Pederzoli P, Scarpa A, Falconi M.
Surgery. 2011 Jul;150(1):75-82.  PMID: 21683859
Link to Abstract

Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression.
Panzuto F, Boninsegna L, Fazio N, Campana D, Pia Brizzi M, Capurso G, Scarpa A, De Braud F, Dogliotti L, Tomassetti P, Delle Fave G, Falconi M.
J Clin Oncol. 2011 Jun 10;29(17):2372-7.  PMID: 21555696
Link to Abstract

Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes.
Haynes AB, Deshpande V, Ingkakul T, Vagefi PA, Szymonifka J, Thayer SP, Ferrone CR, Wargo JA, Warshaw AL, Fernández-del Castillo C.
Arch Surg. 2011 May;146(5):534-8.   PMID: 21576607
Link to Abstract

Glucagonoma and the glucagonoma syndrome – cumulative experience with an elusive endocrine tumour.
Eldor R, Glaser B, Fraenkel M, Doviner V, Salmon A, Gross DJ.
Clin Endocrinol (Oxf). 2011 May;74(5):593-8. PMID: 21470282
Link to Abstract

Serum and ascites chromogranin-a in patients with metastatic neuroendocrine tumors.
Warner RR, Curran T, Shafir MK, Schiano TD, Khaitova V, Kim MK.
Pancreas. 2011 May;40(4):622-6. PMID: 21483253
Link to Abstract

Discrepancies between two alternative staging systems (European Neuroendocrine Tumor Society 2006 and American Joint Committee on Cancer/Union for International Cancer Control 2010) of neuroendocrine neoplasms of the pancreas. A study of 50 cases.
Liszka L, Paj?k J, Mrowiec S, Zieli?ska-Paj?k E, Go?ka D, Lampe P.
Pathol Res Pract. 2011 Apr 15;207(4):220-4. Epub 2011 Feb 26. PMID: 21354717
Link to Abstract

Radiofrequency ablation of neuroendocrine hepatic metastasis. Gamblin TC, Christians K, Pappas SG.
Gamblin TC, Christians K, Pappas SG.
Surg Oncol Clin N Am. 2011 Apr;20(2):273-9, vii-viii. PMID: 21377583
Link to Abstract

High intensity focused ultrasound ablation of pancreatic neuroendocrine tumours: report of two cases.
Orgera G, Krokidis M, Monfardini L, Bonomo G, Della Vigna P, Fazio N, Orsi F.
Cardiovasc Intervent Radiol. 2011 Apr;34(2):419-23. PMID: 20521049
Link to Abstract

Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours.
Medley L, Morel AN, Farrugia D, Reed N, Hayward N, Davies JM, Kirichek O, Thakker RV, Talbot DC.
Br J Cancer. 2011 Mar 29;104(7):1067-70. PMID: 21386841
Link to Abstract

Hepatic Arterial Chemoembolization Using Drug-Eluting Beads in Gastrointestinal Neuroendocrine Tumor Metastatic to the Liver.
Gaur SK, Friese JL, Sadow CA, Ayyagari R, Binkert CA, Schenker MP, Kulke M, Baum R.
Cardiovasc Intervent Radiol. 2011 Mar 24. [Epub ahead of print] PMID: 21431978
Link to Abstract

Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis.
Máthé Z, Tagkalos E, Paul A, Molmenti EP, Kóbori L, Fouzas I, Beckebaum S, Sotiropoulos GC.
Transplantation. 2011 Mar 15;91(5):575-82. PMID: 21200365
Link to Abstract

TNM stage and grade in predicting the prognosis of operated, non-functioning neuroendocrine carcinoma of the pancreas-a single-institution experience.
Sellner F, Thalhammer S, Stättner S, Karner J, Klimpfinger M.
J Surg Oncol. 2011 Feb 24. [Epub ahead of print] PMID: 21360536
Link to Abstract

Peptide Receptor Radionuclide Therapy with Y-DOTATOC and (177)Lu-DOTATOC in Advanced Neuroendocrine Tumors: Results from a Danish Cohort Treated in Switzerland.
Pfeifer AK, Gregersen T, Grønbæk H, Hansen CP, Müller-Brand J, Herskind Bruun K, Krogh K, Kjær A, Knigge U.
Neuroendocrinology. 2011;93(3):189-96. Epub 2011 Feb 19. PMID: 21335949
Link to Abstract

PAX8 is expressed in pancreatic well-differentiated neuroendocrine tumors and in extrapancreatic poorly differentiated neuroendocrine carcinomas in fine-needle aspiration biopsy specimens.
Haynes CM, Sangoi AR, Pai RK.
Cancer Cytopathol. 2011 Feb 15. [Epub ahead of print] PMID: 21328566
Link to Abstract

Everolimus for advanced pancreatic neuroendocrine tumors.
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl
D, Öberg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group.
N Engl J Med. 2011 Feb 10;364(6):514-23. PMID: 21306238

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P.
N Engl J Med. 2011 Feb 10;364(6):501-13. PMID: 21306237
Link to Abstract

Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.
Claringbold PG, Brayshaw PA, Price RA, Turner JH.
Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):302-11. PMID: 21052661
Link to Abstract

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L.
Cancer. 2011 Jan 15;117(2):268-75. Epub 2010 Sep 7. PMID: 20824724
Link to Abstract

Radiofrequency ablation of large size liver tumours using novel plan-parallel expandable bipolar electrodes: initial clinical experience.
Meijerink MR, van den Tol P, van Tilborg AA, van Waesberghe JH, Meijer S, van Kuijk C.
Eur J Radiol. 2011 Jan;77(1):167-71. PMID: 19616911
Link to Abstract

The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
Frilling A, Sotiropoulos GC, Radtke A, Malago M, Bockisch A, Kuehl H, Li J, Broelsch CE.
Ann Surg. 2010 Nov;252(5):850-6. PMID: 21037441
Link to Abstract

Management of intractable hypoglycemia with Yttirum-90 radioembolization in a patient with malignant insulinoma.
Chandra P, Yarandi SS, Khazai N, Jacobs S, Umpierrez GE.
Am J Med Sci. 2010 Nov;340(5):414-7. PMID: 20724903
Link to Abstract

Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma.
Lindholm DP, Eriksson B, Granberg D.
Med Oncol. 2010 Dec 30. [Epub] PMID: 21191667
Link to Abstract

Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up.
Akyildiz HY, Mitchell J, Milas M, Siperstein A, Berber E.
Surgery. 2010 Dec;148(6):1288-93; discussion 1293. PMID: 21134563
Link to Abstract

Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis.
Mayo SC, de Jong MC, Pulitano C, Clary BM, Reddy SK, Gamblin TC, Celinksi SA, Kooby DA, Staley CA, Stokes JB, Chu CK, Ferrero A, Schulick RD, Choti MA, Mentha G, Strub J, Bauer TW, Adams RB, Aldrighetti L, Capussotti L, Pawlik TM.
Ann Surg Oncol. 2010 Dec;17(12):3129-36. 2010 Jun 29. [Epub] PMID: 20585879
Link to Abstract

Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients.
Dong XD, Carr BI.
Med Oncol. 2010 Nov 24. [Epub] PMID: 21107755
Link to Abstract

Analysis of 6,747 Pancreatic Neuroendocrine Tumors for a Proposed Staging System.
J Gastrointest Surg. 2010 Nov 20. [Epub] PMID: 21103949
Link to Abstract

EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors.
Gastrointest Endosc. 2010 Nov 8. [Epub] PMID: 21067742
Link to Abstract

Surgical resection and multidisciplinary care for primary and metastatic pancreatic islet cell carcinomas.
J Gastrointest Surg. 2010 Nov;14(11):1796-803. 2010 May 18. [Epub] PMID: 20480251
Link to Abstract

Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
Cancer Treat Rev. 2010 Nov;36 Suppl 3:S87-94. PMID: 21129617
Link to Abstract

Phase II study of radiopeptide (177)Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.
Eur J Nucl Med Mol Imaging. 2010 Oct 30. [Epub] PMID: 21052661
Link to Abstract

A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.
Cancer Chemother Pharmacol. 2010 Oct 20. [Epub] PMID: 20960192
Link to Abstract

Evaluation of the combination 5-Fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors.
Clin Colorectal Cancer. 2010 Oct 1;9(4):248-54.PMID: 20920998
Link to Abstract

One hundred thirty resections for pancreatic neuroendocrine tumor: evaluating the impact of minimally invasive and parenchyma-sparing techniques.
J Gastrointest Surg. 2010 Oct;14(10):1536-46. PMID: 20824378
Link to Abstract

Surgical treatment of pancreatic endocrine tumours in Italy: results of a prospective multicentre study of 262 cases.
Langenbecks Arch Surg. 2010 Sep 21. [Epub] PMID: 20857140
Link to Abstract

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Cancer. 2010 Sep 7. [Epub] PMID: 20824724
Link to Abstract

Percutaneous radiofrequency ablation approach through the spleen: initial case report for pancreatic tail gastrinoma.
Chin J Cancer. 2010 Sep;29(9):836-41.PMID: 20800027
Link to Abstract

Poorly differentiated endocrine carcinoma of the pancreas responded to gemcitabine: Case report.
World J Gastroenterol. 2010 Aug 14;16(30):3853-6.PMID: 20698050
Link to Abstract

Pancreatic endocrine tumors less than 4 cm in diameter: resect or enucleate? a single-center experience.
Pancreas. 2010 Aug;39(6):825-8.PMID: 20431423
Link to Abstract

Survival following resection of pancreatic endocrine tumors: importance of R-status and the WHO and TNM classification systems.
Scand J Gastroenterol. 2010 Aug;45(7-8):971-9.PMID: 20441530
Link to Abstract

Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach.
Surgery. 2010 Jul 30. PMID: 20674950
Link to Abstract

Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases.
Am J Gastroenterol. 2010 Jun;105(6):1421-9. .PMID: 20087335
Link to Abstract

Parenchyma-preserving resections for small nonfunctioning pancreatic endocrine tumors.
Ann Surg Oncol. 2010 Jun;17(6):1621-7. PMID: 20162460
Link to Abstract

Chemotherapy with 5-Fluorouracil, Cisplatin and Streptozocin for Neuroendocrine Tumours
March 16, 2010

Br J Cancer. 2010 Mar 16,[Epub]. PMID: 20234360
[Abstract]

Surgery and Staging of Pancreatic Neuroendocrine Tumors: A 14-Year Experience
March 12, 2010

J Gastrointestest Surg. 2010 Marc 12. [Epub ahead of print] PMID: 20224984
[Abstract]

Chromogranin A-Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease
March 9, 2010

Ann SurgOncol, 2010 Mar 9. [Epub ahead of print]PMID:20217257
[Abstract]

Peptide Receptor Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors
March 1, 2010

Semin Nucl Med. 2010 Mar;40(2):78-88.PMID: 20113677
[Abstract]

Salvage Therapy with (177)Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors
March 1, 2010

J Nucl Med. 2010 Mar;51(3):383-90. Epub 2010 Feb 11.PMID: 20150247
[Abstract]

131I-Metaiodobenzylguanidine Therapy of Neuroblastoma and Other Neuroendocrine Tumors
March 1, 2010

Semin Nucl Med. 2010 Mar;40(2):153-63.PMID: 20113683
[Abstract]

90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide
March 1, 2010

J Clin Oncol. 2010 Mar 1. [Epub ahead of print]PMID: 20194865
[Abstract]

Non-Functional Neuroendocrine Carcinoma of the Pancreas: Incidence, Tumor Biology, and Outcomes in 2,158 Patients
March 1, 2010

J Gastrointest Surg. 2010 Mar;14(3):541-8. Epub 2009 Dec 9.PMID: 19997980
[Abstract]

Parenchyma-Preserving Resections for Small Nonfunctioning Pancreatic Endocrine Tumors
February 17, 2010

Ann Surg Oncol. 2010 Feb 17. [Epub ahead of print]PMID: 20162460
[Abstract]

177Lu-[DOTA0,Tyr3] Octreotate Therapy in Patients with Disseminated Neuroendocrine Tumors: Analysis of Dosimetry with Impact on Future Therapeutic Strategy
February 15, 2010

Cancer. 2010 Feb 15;116(4 Suppl):1084-92.PMID: 20127957
[Abstract]

Staged Surgery with Neoadjuvant 90Y-DOTATOC Therapy for Down-Sizing Synchronous Bilobular Hepatic Metastases from a Neuroendocrine Pancreatic Tumor
February 1, 2010

Langenbecks Arch Surg. 2010 Feb;395(2):185-92. Epub 2009 Jun 9.PMID: 19506898
[Abstract]

Treatment with Tandem [90Y]DOTA-TATE and [177Lu] DOTA-TATE of Neuroendocrine Tumors Refractory to Conventional Therapy: Preliminary Results
February 1, 2010

Q J Nucl Med Mol Imaging. 2010 Feb;54(1):84-91.PMID: 20168290
[Abstract]

[(177)Lu-DOTA(0)-Tyr(3)]-Octreotate Treatment in Patients with Disseminated Gastroenteropancreatic Neuroendocrine Tumors: The Value of Measuring Absorbed Dose to the Kidney
January 12, 2010

World J Surg. 2010 Jan 12. [Epub ahead of print]PMID: 20066413
[Abstract]

Cisplatin and Etoposide as First-Line Chemotherapy for Poorly Differentiated Neuroendocrine Carcinoma of the Hepatobiliary Tract and Pancreas
January 4, 2010

Jpn J Clin Oncol. 2010 Jan 4. [Epub ahead of print]PMID: 20047862
[Abstract]

Clinical Response of Large Cell Neuroendocrine Carcinoma of the Lung to Perioperative Adjuvant Chemotherapy
January 1, 2010

Anticancer Drugs. 2010 Jan;21(1):89-93.PMID: 19770636
[Abstract]

Daily Oral Everolimus Activity in Patients with Metastatic Pancreatic Neuroendocrine Tumors after Failure of Cytotoxic Chemotherapy: A Phase II Trial
January 1, 2010

J Clin Oncol. 2010 Jan 1;28(1):69-76. Epub 2009 Nov 23.PMID: 19933912
[Abstract]

Efficacy of using a Standard Activity of (131)I-MIBG Therapy in Patients with Disseminated Neuroendocrine Tumours
December 17, 2009

Eur J Nucl Med Mol Imaging. 2009 Dec 17. [Epub ahead of print]PMID: 20016892
[Abstract]

Neoadjuvant Peptide Receptor Radionuclide Therapy for an Inoperable Neuroendocrine Pancreatic Tumor
December 14, 2009

World J Gastroenterol. 2009 Dec 14;15(46):5867-70.PMID: 19998512
[Abstract]

Impact of Multiphase 68Ga-DOTATOC-PET/CT on Therapy Management in Patients with Neuroendocrine Tumors
December 9, 2009

Neuroendocrinology. 2010;91(1):101-9. Epub 2009 Dec 9.PMID: 19996582
[Abstract]

Phase III Trial of Chemotherapy using 5-Fluorouracil and Streptozotocin Compared with Interferon Alpha for Advanced Carcinoid Tumors: FNCLCC-FFCD 9710
December 1, 2009

Endocr Relat Cancer. 2009 Dec;16(4):1351-61. Epub 2009 Sep 2.PMID: 19726540
[Abstract]

Sunitinib Paves the Way for Targeted Therapies in Neuroendocrine Tumors
December 1, 2009

Target Oncol. 2009 Dec;4(4):253-4. Epub 2009 Nov 13.PMID: 19911111
[Abstract]

Radiotherapy for Pancreatic Neuroendocrine Tumors
November 15, 2009

Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1196-200. Epub 2009 Mar 26.PMID: 19327905
[Abstract]

Continuous 5-Fluorouracil Infusion plus Long Acting Octreotide in Advanced Well-Differentiated Neuroendocrine Carcinomas. A Phase II Trial of the Piemonte Oncology Network
November 3, 2009

BMC Cancer. 2009 Nov 3;9:388.PMID: 19886987
[Abstract]

A Successful Two-Stage Treatment with CDDP and CPT-11 for Pancreatic Neuroendocrine Carcinoma with Liver Metastasis
November 1, 2009

Gan To Kagaku Ryoho. 2009 Nov;36(11):1897-900. Japanese. PMID: 19920396
[Abstract]

Refractory Neuroendocrine Tumor-Response to Liposomal Doxorubicin and Capecitabine
November 1, 2009

Nat Rev Clin Oncol. 2009 Nov;6(11):670-4.PMID: 19861994
[Abstract]

Liver Metastases of Neuroendocrine Tumors: Treatment with Hepatic Transarterial Chemotherapy using Two Therapeutic Protocols
October 1, 2009

AJR Am J Roentgenol. 2009 Oct;193(4):941-7.PMID: 19770314
[Abstract]

Combined Liver Surgery and RFA for Patients with Gastroenteropancreatic Endocrine Tumors Presenting with More Than 15 Metastases to the Liver
October 1, 2009

Eur J Surg Oncol. 2009 Oct;35(10):1092-7. Epub 2009 May 21.PMID: 19464140
[Abstract]

High-Dose Octreotide Acetate for Management of Gastroenteropancreatic Neuroendocrine Tumors
October 1, 2009

Anticancer Res. 2009 Oct;29(10):4127-30.PMID: 19846960
[Abstract]

High-Administered Activity In-111 Octreotide Therapy with Concomitant Radiosensitizing 5FU Chemotherapy for Treatment of Neuroendocrine Tumors: Preliminary Experience
October 1, 2009

Cancer Biother Radiopharm. 2009 Oct;24(5):527-33.PMID: 19877882
[Abstract]

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors: A Report from the PROMID Study Group
October 1, 2009

J Clin Oncol. 2009 Oct 1;27(28):4656-63. Epub 2009 Aug 24.PMID: 19704057
[Abstract]

Diagnosis and Treatment of Pancreatic Vasoactive Intestinal Peptide Endocrine Tumors
October 1, 2009

Pancreas.2009 Oct;38(7):811-4.PMID:19657309
[Abstract]

Sandostatin LAR for Advanced Neuroendocrine Tumors
October 1, 2009
more

Pancreatic Islet Cell Carcinoma Presenting with Concurrent Cushing’s and Zollinger-Ellison Syndromes: Case Series and Literature Review
September 18, 2009

Eur J Gastroenterol Hepatol. 2009 Sep 18. [Epub]. PMID: 19770666
[Abstract]

Radiofrequency Ablation of Solitary Pancreatic Insulinoma in a Patient with Episodes of Severe Hypoglycemia
September 1, 2009

Eur J Gastroenterol Hepatol. 2009 Sep;21(9):1097-101. PMID: 19685572
[Abstract]

Pancreatic Incidentalomas: High Rate of Potentially Malignant Tumors
September 1, 2009

J Am Coll Surg. 2009 Sep;209(3):313-9. PMID: 19717035
[Abstract]

Pancreatic Insulinoma: A Surgical Experience
September 1, 2009

World J Surg. 2009 Sep;33(9):1966-70. PMID: 19629581
[Abstract]

Robotic Resection of Intraductal Neoplasm of the Pancreas
August 21, 2009

J Laparoendosc Adv Surg Tech A. 2009 Aug 21. [Epub]. PMID: 19698031
[Abstract]

Risk Factors for Sporadic Pancreatic Endocrine Tumors: A Case-Control Study of Prospectively Evaluated Patients
August 18, 2009

Am J Gastroenterol. 2009 Aug 18. [Epub ahead of print] PMID: 19690522
[Abstract]

A Preoperative Prognostic Score for Resected Pancreatic and Periampullary Neuroendocrine Tumours
August 14, 2009

Pancreatology. 2009 Aug 14;9(5):670-676. [Epub]. PMID: 19684431
[Abstract]

Pancreatic Endocrine Tumors: A Large Single-Center Experience
August 6, 2009

Pancreas. 2009 Aug 6. [Epub]. PMID: 19672207
[Abstract]

Diagnosis and Treatment of Pancreatic Vasoactive Intestinal Peptide Endocrine Tumors
August 5, 2009

Pancreas. 2009 Aug 5. [Epub]. PMID: 19657309
[Abstract]

A Fuller Understanding of Pancreatic Neuroendocrine Tumours Combined with Aggressive Management Improves Outcome
August 4, 2009

Pancreatology. 2009 Aug 4;9(5):583-600. [Epub]. PMID: 19657214
[Abstract]

Management of Advanced Neuroendocrine Tumors with Hepatic Metastasis
August 3, 2009

J Clin Gastroenterol. 2009 Aug 3. [Epub]. PMID: 19654558
[Abstract]

Detection of Unknown Primary Neuroendocrine Tumours (CUP-NET) using (68)Ga-DOTA-NOC Receptor PET/CT
July 18, 2009

Eur J Nucl Med Mol Imaging. 2009 Jul 18. [Epub]. PMID: 19618183
[Abstract]

CEACAM1 Expression in Pancreatic Endocrine Tumors
July 1, 2009

Appl Immunohistochem Mol Morphol. 2009 Jul;17(4):286-93. PMID: 19349857
[Abstract]

Successful Control of Intractable Hypoglycemia Using Rapamycin in an 86-year Old Man with a Pancreatic Insulin-Secreting Islet Cell Tumor and Metastases
June 30, 2009

J Clin Endocrinol Metab. 2009 Jun 30. [Epub] PMID: 19567519
[Abstract]

Small Pancreatic and Periampullary Neuroendocrine Tumors: Resect or Enucleate?
June 23, 2009

J Gastrointest Surg. 2009 Jun 23. [Epub] PMID: 19548038
[Abstract]

Staged Surgery With Neoadjuvant (90)Y-DOTATOC Therapy for Down-sizing Synchronous Bilobular Hepatic Metastases from a Neuroendocrine Pancreatic Tumor
June 9, 2009

Langenbecks Arch Surg. 2009 Jun 9. [Epub] PMID: 19506898
[Abstract]

Gemcitabine and Oxaliplatin Combination Chemotherapy for Metastatic Well-differentiated Neuroendocrine Carcinomas: A Single-center Experience
May 26, 2009

Cancer. 2009 May 26. [Epub] PMID: 19472402
[Abstract]

Novel and Evolving Therapies in the Treatment of Malignant Phaeochromocytoma: Experience with the mTOR Inhibitor Everolimus (RAD001)
May 7, 2009

Horm Metab Res. 2009 May 7. [Epub] PMID: 19424940
[Abstract]

Laparoscopic Surgery for Pancreatic Insulinomas: A Single-Institution Experience of 29 Cases
May 1, 2009

J Gastrointest Surg. 2009 May;13(5):945-50. PMID: 19224293
[Abstract]

Progress in the Treatment of Neuroendocrine Tumors
May 1, 2009

ICurr Oncol Rep. 2009 May;11(3):193-9. PMID: 19336011
[Abstract]

Prolonged Survival after Hepatic Artery Embolization in Patients with Midgut Carcinoid Syndrome
May 1, 2009

Br J Surg. 2009 May;96(5):517-21. PMID: 19358175
[Abstract]

Liver Resection Versus Other Treatments for Neuroendocrine Tumours in Patients with Resectable Liver Metastases
April 15, 2009

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007060. PMID: 19370671
[Abstract]

Development of the Norfolk Quality of Life Tool for Assessing Patients with Neuroendocrine Tumors
April 1, 2009

Pancreas. 2009 Apr;38(3):e87-95. PMID: 19276865
[Abstract]

Radiotherapy for Pancreatic Neuroendocrine Tumors
March 25, 2009

Int J Radiat Oncol Biol Phys. 2009 Mar 25 [Epub]. PMID: 19327905
[Abstract]

Aggressive Multi-visceral Pancreatic Resections for Locally Advanced Neuroendocrine Tumours. Is it Worth it?
March 18, 2009

JOP. 2009 Mar 18;10(3):276-9. PMID: 19454819
[Abstract]

A Rare Surgical Case of Multiple Liver Resections for Recurrent Liver Metastases from Pancreatic Gastrinoma: Liver and Vena Cava Resection
March 10, 2009

J Hepatobiliary Pancreat Surg. 2009 Mar 10 [Epub]. PMID: 19267257
[Abstract]

Management of the Primary Tumor in Patients with Metastatic Pancreatic Neuroendocrine Tumor: A Contemporary Single-Institution Review
March 1, 2009

Am J Surg. 2009 Mar;197(3):376-81. PMID: 19245918
[Abstract]

Laparoscopic Management of Insulinomas
January 21, 2009

Br J Surg. 2009 Jan 21;96(2):185-190. [Epub]. PMID: 19160363
[Abstract]

Intraindividual Comparison of (68)Ga-DOTA-TATE and (18)F-DOPA PET in Patients With Well-Differentiated Metastatic Neuroendocrine Tumours
January 10, 2009

Eur J Nucl Med Mol Imaging. 2009 Jan 10. [Epub]. PMID: 19137293
[Abstract]

Expression Pattern and Functional Relevance of Epidermal Growth Factor Receptor and Cyclooxygenase-2: Novel Chemotherapeutic Targets in Pancreatic Endocrine Tumors?
January 1, 2009

Am J Gastroenterol. 2009 Jan;104(1):171-81. PMID: 19098866
[Abstract]

Diagnosis and Treatment of Pheochromocytoma in an Academic Hospital from 1997 to 2007
January 1, 2009

Am J Med. 2009 Jan;122(1):85-95. PMID: 19114176
[Abstract]

Outcome of Treating Advanced Neuroendocrine Tumours With Radiolabelled Somatostatin Analogues
January 1, 2009

Clin Transl Oncol. 2009 Jan;11(1):48-53. PMID: 19155204
[Abstract]

The Clinical Value of [18F]-Fluoro-Dihydroxyphenylalanine Positron Emission Tomography in Primary Diagnosis, Staging and Restaging of Neuroendocrine Tumors
December 16, 2008

Endocr Relat Cancer. 2008 Dec 16. [Epub]. PMID: 19088184
[Abstract]

Reclassification of Neuroendocrine Tumors Improves the Separation of Carcinoids and the Prediction of Survival
December 3, 2008

J Thorac Oncol. 2008 Dec;3(12):1410-5. PMID: 19057265
[Abstract]

Combination Therapy With Histone Deacetylase Inhibitors and Lithium Chloride: A Novel Treatment for Carcinoid Tumors
November 22, 2008

Ann Surg Oncol. 2008 Nov 22. [Epub]. PMID: 19030935
[Abstract]

Intraoperative Hand Held Gamma Probe Detection of a Recurrent Nonfunctional Neuroendocrine Tumor
November 3, 2008

JOP. 2008 Nov 3;9(6):704-7. PMID: 18981551
[Abstract]

Typical and Atypical Carcinoid Tumours: 20-year Experience with 89 Patients
October 24, 2008

J Cardiovasc Surg (Torino). 2008 Oct 24. [Epub] PMID: 18948870
[Abstract]

Surgery versus Radiochemotherapy for Resectable Locally Invasive Pancreatic Cancer: Final Results of a Randomized Multi-Institutional Trial
November 1, 2008

Surg Today. 2008 Nov;38(11):1021-1028. Epub 2008 Oct 29. PMID: 18958561
[Abstract]

Aggressive Surgical Resection in the Management of Pancreatic Neuroendocrine Tumors: When is it Indicated?
October 1, 2008

Cancer Control. 2008 Oct;15(4):314-21. PMID: 18813199
[Abstract]

The Impact of Preoperative Endoscopic Ultrasound on the Surgical Management of Pancreatic Neuroendocrine Tumours
October 1, 2008

Can J Gastroenterol. 2008 Oct;22(10):817-20. PMID: 18925304
[Abstract]

Surgical Approach and Perioperative Complications Determine Short-Term Outcomes in Patients with Insulinoma: Results of a Bi-Institutional Study
September 30, 2008

Ann Surg Oncol. 2008 Sep 30. [Epub] PMID: 18825460
[Abstract]

Liver Metastases of Neuroendocrine Carcinomas: Interventional Treatment via Transarterial Embolization, Chemoembolization and Thermal Ablation
September 29, 2008

Eur J Radiol. 2008 Sep 29. [Epub] PMID: 18829195
[Abstract]

Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-grade Neuroendocrine Tumors: Results of a Phase II Study
September 10, 2008

J Clin Oncol. 2008 Sep 10;26(26):4311-8. PMID: 18779618
[Abstract]

Clinical Applications of 68Ga-DOTANOC in Neuroendocrine Tumours
September 1, 2008

Minerva Endocrinol. 2008 Sep;33(3):277-81. PMID: 18846030
[Abstract]

Optimizing MIBG Therapy of Neuroendocrine Tumors: Preclinical Evidence of Dose Maximization and Synergy
August 1, 2008

Nucl Med Biol. 2008 Aug;35 Suppl 1:S9-20. PMID: 18707637
[Abstract]

Activity of Sunitinib in Patients with Advanced Neuroendocrine Tumors
July 10, 2008

J Clin Oncol. 2008 Jul 10;26(20):3403-10. PMID: 18612155
[Abstract]

Neuroendocrine Tumors: A registry of 1,000 Patients
July 1, 2008

Rev Assoc Med Bras. 2008 Jul-Aug;54(4):305-7. PMID: 18719787
[Abstract]

Phase I Trial of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir and Chemoradiation for Locally Advanced Pancreatic Cancer
June 1, 2008

J Clin Oncol. 2008 Jun 1;26(16):2699-706. PMID: 18509182
[Abstract]

Radioembolization for Unresectable Neuroendocrine Hepatic Metastases Using Resin 90Y-Microspheres: Early Results in 148 Patients
June 1, 2008

Am J Clin Oncol. 2008 Jun;31(3):271-9. PMID: 18525307
[Abstract]

Comparison Between (68)Ga-DOTA-NOC and (18)F-DOPA PET for the Detection of Gastro-Entero-Pancreatic and Lung Neuro-Endocrine Tumours
April 17, 2008

Eur J Nucl Med Mol Imaging. 2008 Apr 17. [Epub]PMID: 18418596
[Abstract]

Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: A Random Assignment Phase II Study of Depot Octreotide with
Bevacizumab and Pegylated Interferon Alpha-2b March 10, 2008

J Clin Oncol. 2008 Mar 10;26(8):1316-23. PMID: 18323556
[Abstract]

Antitumor Activity of Rapamycin and Octreotide as Single Agents or in Combination in Neuroendocrine Tumors
March 1, 2008

Endocr Relat Cancer. 2008 Mar;15(1):257-66. PMID: 18310292
[Abstract]

Complete Response of CNS-Involved Olfactory Neuroendocrine Tumor using Multimodal Therapy
March 1, 2008

Onkologie. 2008 Mar;31(3):119-21. PMID: 18322415
[Abstract]

Treatment with Combined Streptozotocin and Liposomal Doxorubicin in Metastatic Endocrine Pancreatic Tumors
February 18, 2008

Neuroendocrinology. 2008 Feb 18. PMID: 18285678
[Abstract]

Is Laparoscopic Resection Adequate in Patients with Neuroendocrine Pancreatic Tumors?
February 11, 2008
World J Surg. 2008 Feb 11. PMID: 18264824
[Abstract]

Thymic Carcinoid Responds to Neoadjuvant Therapy with Sunitinib and Octreotide: A Case Report
January 1, 2008

J Thorac Oncol. 2008 Jan;3(1):94-7. PMID: 18166847
[Abstract]

Diagnostic Value of CDX-2 and TTF-1 Expressions in Separating Metastatic Neuroendocrine Neoplasms of Unknown Origin
December 1, 2007

Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):407-14. PMID: 18091383
[Abstract]

Type 1 and 2 Gastric Carcinoid Tumors: Long-Term Follow-up of the Efficacy of Treatment with a Slow-Release Somatostatin Analogue
November 1, 2007

Eur J Gastroenterol Hepatol. 2007 Nov;19(11):1021-5. PMID: 18049175
[Abstract]

Radio-Guided Surgery in Neuroendocrine Tumors
September 15, 2007

J Surg Oncol. 2007 Sep 15;96(4):309-15. PMID: 17726664
[Abstract]

Endocrine Pancreatic Tumors with Glucagon Hypersecretion: A Retrospective Study of 23 Cases During 20 Years
September 1, 2007

Med Oncol. 2007;24(3):330-7. PMID: 17873310
[Abstract]

Laparoscopic Enucleation of Pancreatic Insulinomas
August 1, 2007

J Laparoendosc Adv Surg Tech A. 2007 Aug;17(4):399-401. PMID: 17705715
[Abstract]

RadioFrequency Thermal Ablation of Metastatic Neuroendocrine Tumors in the Liver
August 1, 2007

Curr Treat Options Oncol. 2007 Aug;8(4):322-30. PMID: 18084730
[Abstract]

Microwave Hepatic Ablation: Initial Experience of Safety and Efficacy
July 24, 2007

J Surg Oncol. 2007 Jul 24. PMID: 17654527
[Abstract]

Somatostatinoma: Clinico-Pathological Features of Three Cases and Literature Reviewed
July 20, 2007

J Gastroenterol Hepatol. 2007 Jul 20. PMID: 17645474
[Abstract]

Chemoembolization and Bland Embolization of Neuroendocrine Tumor Metastases to the Liver
July 1, 2007

J Vasc Interv Radiol. 2007 Jul;18(7):847-55. PMID: 17609443
[Abstract]

Laparoscopic Radiofrequency Ablation of Neuroendocrine Liver Metastases: A 10-Year Experience Evaluating Predictors of Survival
July 1, 2007

Surgery. 2007 Jul;142(1):10-9. PMID: 17629995
[Abstract]

[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a Highly Efficient Radiotherapeutic for Glucagon-Like Peptide-1 Receptor-Targeted Therapy for Insulinoma
June 15, 2007

Clin Cancer Res. 2007 Jun 15;13(12):3696-705. PMID: 17575235
[Abstract]

Chromogranin A as a Marker of Neuroendocrine Neoplasia: An Italian Multicenter Study
June 1, 2007

Endocr Relat Cancer. 2007 Jun;14(2):473-82. PMID: 17639060
[Abstract]

Successful Pancreatectomy with En-Bloc Resection of the Celiac Artery and Portal Vein for Pancreatic Endocrine Carcinoma
June 1, 2007

Hepatogastroenterology. 2007 Jun;54(76):1269-71. PMID: 17629086
[Abstract]

A Malignant Nonfunctioning Pancreatic Endocrine Tumor with a Unique Pattern of Intraductal Growth
May 29, 2007

J Hepatobiliary Pancreat Surg. 2007;14(3):318-23. Epub 2007 May 29. PMID: 17520210
[Abstract]

Comparison of (68)Ga-DOTATOC PET and (111)In-DTPAOC (Octreoscan) SPECT in Patients with Neuroendocrine Tumours
May 23, 2007

Eur J Nucl Med Mol Imaging. 2007 May 23. PMID: 17520251
[Abstract]

Pancreatic VIPomas: Subject Review and One Institutional Experience
May 18, 2007

J Gastrointest Surg. 2007 May 18. PMID: 17510774
[Abstract]

Effective Treatment of Locally Advanced Endocrine Tumors of the Pancreas with Chemoradiotherapy
May 16, 2007

Neuroendocrinology. 2007;85(4):216-20. PMID: 17541257
[Abstract]

Temozolomide as Monotherapy is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors
May 15, 2007

Clin Cancer Res. 2007 May 15;13(10):2986-91. PMID: 17505000
[Abstract]

Aggressive Pancreatic Resection for Primary Pancreatic Neuroendocrine Tumor: Is it Justifiable?
May 1, 2007

Am J Surg. 2007 May;193(5):610-3; discussion 613. PMID: 17434366
[Abstract]

Emerging Therapies for the Treatment of Patients with Advanced Neuroendocrine Tumors
May 1, 2007

Expert Opin Emerg Drugs. 2007 May;12(2):253-70. PMID: 17604500
[Abstract]

Surgery in Malignant Pancreatic Neuroendocrine Tumors
April 27, 2007

J Surg Oncol. 2007 Apr 27. PMID: 17469119
[Abstract]

Surgical Strategies and Predictors of Outcome for Malignant Neuroendocrine Tumors of the Pancreas
April 19, 2007

J Gastroenterol Hepatol. 2007 Apr 19. PMID: 17489964
[Abstract]

The Role of Intra-Arterial Calcium Stimulation Test with Hepatic Venous Sampling (IACS) in the Management of Occult Insulinomas
April 12, 2007

Ann Surg Oncol. 2007 Apr 12. PMID: 17431724
[Abstract]

Differential Diagnosis of Non-Functional Islet Cell Tumor and Pancreatic Carcinoma With Sonography
April 3, 2007

Eur J Radiol. 2007 Apr 3. PMID: 17412543
[Abstract]

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy And CT
April 1, 2007

J Nucl Med. 2007 Apr;48(4):508-18. PMID: 17401086
[Abstract]

Evolving Patterns in the Detection and Outcomes of Pancreatic Neuroendocrine Neoplasms: The Massachusetts General Hospital Experience from 1977 to 2005
April 1, 2007

Arch Surg. 2007 Apr;142(4):347-54. PMID: 17438169
[Abstract]

Localisation and Surgical Treatment of Insulinomas
April 1, 2007

Int J Clin Pract. 2007 Apr;61(4):558-61. PMID: 17394431
[Abstract]

Phase I Study of Carboplatin in Combination with Gemcitabine and Irinotecan in Patients with Solid Tumors: Preliminary Evidence of Activity in Small Cell and Neuroendocrine Carcinomas
April 1, 2007

Cancer. 2007 Apr 1;109(7):1413-9 PMID: 17326096
[Abstract]

Surgical Approach to Insulinomas: Are Pre-Operative Localisation Tests Necessary?
April 1, 2007

Ann R Coll Surg Engl. 2007 Apr;89(3):212-7. PMID: 17394700
[Abstract]

Surgical Treatment of Pancreatic Endocrine Neoplasms
April 1, 2007

Am J Surg. 2007 Apr;193(4):460-5. PMID: 17368289
[Abstract]

Usefulness of F-18 FDG-PET in Detection of Multiple Endocrine Tumors with Duodenal Carcinoid
March 27, 2007

Comput Med Imaging Graph. 2007 Mar 22. PMID: 17383156
[Abstract]

Pancreatic Endocrine Tumors with Intraductal Growth into the Main Pancreatic Duct and Tumor Thrombus within the Portal Vein: A Case Report and Review of the Literature
March 15, 2007

Intern Med. 2007;46(6):273-7. Epub 2007 Mar 15. PMID: 17379993
[Abstract]

The Nestin Progenitor Lineage is the Compartment of Origin for Pancreatic Intraepithelial Neoplasia
March 13, 2007

Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4437-42. PMID: 17360542
[Abstract]

Anatomic and Functional Imaging of Metastatic Carcinoid Tumors.
March 1, 2007

Radiographics. 2007 Mar-Apr;27(2):455-77. PMID: 17374863
[Abstract]

Biochemistry of Neuroendocrine Tumours
March 1, 2007

Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):33-41. PMID: 17382264
[Abstract]

Cytotoxic Treatment Including Embolization/Chemoembolization for Neuroendocrine Tumours
March 1, 2007

Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):131-44. PMID: 17382269
[Abstract]

Imaging of Neuroendocrine Tumours (CT/MR/US)
March 1, 2007

Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):43-68. PMID: 17382265
[Abstract]

Liver Embolization with Trisacryl Gelatin Microspheres (Embosphere) in Patients with Neuroendocrine Tumors
March 1, 2007

Acta Radiol. 2007 Mar;48(2):180-5. PMID: 17354139
[Abstract]

Orthotopic Liver or Multivisceral Transplantation as Treatment of Metastatic Neuroendocrine Tumors
March 1, 2007

Liver Transpl. 2007 Mar;13(3):327-33. PMID: 17318853
[Abstract]

Race, Socioeconomic Status, Treatment, and Survival Time among Pancreatic Cancer Cases in California
March 1, 2007

Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):546-52. PMID: 17372250
[Abstract]

Surgery on Neuroendocrine Tumours
March 1, 2007

Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):87-109. PMID: 17382267
[Abstract]

Endoscopic Resection of an Ampullary Carcinoid Presenting with Upper Gastrointestinal Bleeding: A Case Report and Review of the Literature
February 28, 2007

World J Gastroenterol. 2007 Feb 28;13(8):1268-70. PMID: 17451212
[Abstract]

Aggressive Surgery Improves Long-Term Survival in Neuroendocrine Pancreatic Tumors: An Institutional Experience
February 1, 2007

Ann Surg. 2007 Feb;245(2):273-281. PMID: 17245182
[Abstract]

A Review of the Current Clinical Trials for Gastroenteropancreatic Neuroendocrine Tumours
February 1, 2007

Expert Opin Investig Drugs. 2007 Feb;16(2):219-24. PMID: 17243941
[Abstract]

Functioning and Nonfunctioning Neuroendocrine Tumors of the Pancreas
January 1, 2007

Curr Opin Oncol. 2007 Jan;19(1):30-5. PMID: 17133109
[Abstract]

Clinical and in Vitro Studies of Imatinib in Advanced Carcinoid Tumors
January 1, 2007

Clin Cancer Res. 2007 Jan 1;13(1):234-40. PMID: 17200360
[Abstract]

Large Bowel Carcinoid Tumors
January 1, 2007

Curr Opin Gastroenterol. 2007 Jan;23(1):74-8. PMID: 17133089
[Abstract]

An Aggressive Surgical Approach Leads to Long-Term Survival in Patients with Pancreatic Endocrine Tumors
December 1, 2006

Ann Surg. 2006 Dec;244(6):845-853. PMID: 17122609
[Abstract]

Predictive Factors of Efficacy of the Somatostatin Analogue Octreotide as First Line Therapy for Advanced Pancreatic Endocrine Carcinoma
December 1, 2006

Endocr Relat Cancer. 2006 Dec;13(4):1213-21. PMID: 17158766
[Abstract]

Treatment with (90)Y- and (177)Lu-DOTATOC in Patients with Metastatic Neuroendocrine Tumors
December 1, 2006

Surgery. 2006 Dec;140(6):968-76; discussion 976-7. PMID: 17188146
[Abstract]

Lanreotide Autogel Every 6 Weeks Compared with Lanreotide Microparticles Every 3 Weeks in Patients with Well Differentiated Neuroendocrine Tumors: A Phase III Study
November 15, 2006

Cancer. 2006 Nov 15;107(10):2474-81. PMID: 17054107
[Abstract]

Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: Which Peptide is Preferable for PRRT?
November 1, 2006

Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1346-51. PMID: 16847654
[Abstract]

Identification of Potential Therapeutic Targets by Gene-Expression Profiling in Pancreatic Endocrine Tumors
November 1, 2006

Gastroenterology. 2006 Nov;131(5):1597-610. PMID: 17064702
[Abstract]

MRI of Islet Cell Tumors of the Pancreas
November 1, 2006

AJR Am J Roentgenol. 2006 Nov;187(5):W472-80. PMID: 17056877
[Abstract]

Prospective Study of Adjuvant Chemotherapy for Pulmonary Large Cell Neuroendocrine Carcinoma
November 1, 2006

Ann Thorac Surg. 2006 Nov;82(5):1802-7. PMID: 17062251
[Abstract]

Review Article: Pathogenesis and Management of Gastric Carcinoid Tumours
November 1, 2006

Aliment Pharmacol Ther. 2006 Nov 1;24(9):1305-20. PMID: 17059512
[Abstract]

Are Capecitabine and Oxaliplatin (XELOX) Suitable Treatments for Progressing Low-Grade and High-Grade Neuroendocrine Tumours?
August 26, 2006

Cancer Chemother Pharmacol. 2006 Aug 26. PMID: 16937105
[Abstract]

Carcinoid Tumors
August 1, 2006

Am Fam Physician. 2006 Aug 1;74(3):429-34. PMID: 16913162
[Abstract]

Gastrointestinal Carcinoids: The Evolution of Diagnostic Strategies
August 1, 2006

J Clin Gastroenterol. 2006 Aug;40(7):572-82. PMID: 16917396
[Abstract]

Phase II Trial of Paclitaxel, Carboplatin, and Etoposide in Advanced Poorly Differentiated Neuroendocrine Carcinoma: A Minnie Pearl Cancer Research Network Study
August 1, 2006

J Clin Oncol. 2006 Aug 1;24(22):3548-54. PMID: 16877720
[Abstract]

Resection of Pancreatic Neuroendocrine Tumors: Results of 70 Cases
August 1, 2006

Arch Surg. 2006 Aug;141(8):765-9; discussion 769-70. PMID: 16924083
[Abstract]

Carcinoid Tumors
July 1, 2006

Surg Oncol Clin N Am. 2006 Jul;15(3):463-78. PMID: 16882492
[Abstract]
Endocrine Tumors of the Pancreas
July 1, 2006

Endocrinol Metab Clin North Am. 2006 Jun;35(2):431-47, xii. PMID: 16632104
[Abstract]

Imaging of Neuroendocrine Tumors
July 1, 2006

Semin Nucl Med. 2006 Jul;36(3):228-47. PMID: 16762613
[Abstract]

Liver Transplantation for Patients with Metastatic Endocrine Tumors: Single-Center Experience with 15 Patients
July 1, 2006

Liver Transpl. 2006 Jul;12(7):1089-96. PMID: 16799958
[Abstract]

Neuroendocrine Tumors of the Pancreas, Excluding Gastrinoma
July 1, 2006

Surg Oncol Clin N Am. 2006 Jul;15(3):497-510. PMID: 16882494
[Abstract]

Treatment of Metastatic Disease in Patients with Neuroendocrine Tumors
July 1, 2006

Surg Oncol Clin N Am. 2006 Jul;15(3):511-33, viii. PMID: 16882495
[Abstract]

Update on Pancreatic Endocrine Tumors
July 1, 2006

Arch Pathol Lab Med. 2006 Jul;130(7):963-6. PMID: 16831051
[Abstract]

A Phase II Trial of Irinotecan and Cisplatin in Patients with Metastatic Neuroendocrine Tumors
June 1, 2006

Dig Dis Sci. 2006 Jun;51(6):1033-8. PMID: 16865563
[Abstract]

Management of Pancreatic Endocrine Tumors in Multiple Endocrine Neoplasia Type 1
May 1, 2006

World J Surg. 2006 May;30(5):643-53. PMID: 16680581
[Abstract]

Therapeutic Options for Gastrointestinal Carcinoids
May 1, 2006

Clin Gastroenterol Hepatol. 2006 May;4(5):526-47. PMID: 16630755
[Abstract]

Survival and Response After Peptide Receptor Radionuclide Therapy with [90Y-DOTA0,Tyr3]octreotide in Patients with Advanced Gastroenteropancreatic Neuroendocrine Tumors
April 1, 2006

Semin Nucl Med. 2006 Apr;36(2):147-56. PMID: 16517236
[Abstract]

Multi-Detector Row CT of Pancreatic Islet Cell Tumors
March 1, 2006

Radiographics. 2006 Mar-Apr;26(2):453-64. PMID: 16549609
[Abstract]

Surgery for Gastrinoma and Insulinoma in Multiple Endocrine Neoplasia Type 1
February 1, 2006

J Natl Compr Canc Netw. 2006 Feb;4(2):148-53. PMID: 16451771
[Abstract]

Phase II Study of Temozolomide and Thalidomide in Patients with Metastatic Neuroendocrine Tumors
January 20, 2006

J Clin Oncol. 2006 Jan 20;24(3):401-6. PMID: 16421420
[Abstract]

Differences in Survival for Patients with Resectable Versus Unresectable Metastases From Pancreatic Islet Cell Cancer
January 1, 2006

J Gastrointest Surg. 2006 Jan 1;10(1):138-145. PMID: 16368504
[Abstract]

Efficacy and Tolerability of Pegylated IFN-alpha in Patients with Neuroendocrine Gastroenteropancreatic Carcinomas
January 1, 2006

Anticancer Res. 2006 Jan-Feb;26(1B):703-7. PMID: 16739341
[Abstract]

Neuroendocrine Tumors of the Pancreas
January 1, 2006

Trop Gastroenterol. 2006 Jan-Mar;27(1):4-10. PMID: 16910053
[Abstract]

Selective Hepatic Artery Embolization for Treatment of Patients with Metastatic Carcinoid and Pancreatic Endocrine Tumors
January 1, 2006

Cancer Control. 2006 Jan;13(1):72-8 PMID: 16508629
[Abstract]

Somatostatin Analogues in Treatment of Gastrointestinal and Pancreatic Neuroendocrine Tumors
January 1, 2006

Klin Med (Mosk). 2006;84(4):4-8. PMID: 16755846
[Abstract]

Targeted Radionuclide Therapy with 90Y-DOTATOC in Patients with Neuroendocrine Tumors
January 1, 2006

Anticancer Res. 2006 Jan-Feb;26(1B):703-7. PMID: 16739341
[Abstract]

The Role of Cytoreductive Hepatic Surgery as an Adjunct to the Management of Metastatic Neuroendocrine Carcinomas
January 1, 2006

Cancer Control. 2006 Jan;13(1):61-71. PMID: 16508628
[Abstract]